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Background: Although highly active antiretroviral therapy (HAART) has significantly improved the 
survival of human immunodeficiency virus (HIV)-infected patients there are increased concerns 
regarding the onset of co-morbidities (e.g. cardio-metabolic complications) and mortalities. Although 
South Africa is burdened with the highest number of HIV-infected individuals globally, there is a relative 
paucity of data regarding potential links between HIV infection, HAART and cardio-metabolic 
risk/onset.  
Methods: This cross-sectional study therefore investigated the prevalence of cardio-metabolic risk 
factors in HIV-infected individuals within the Cape Winelands region of South Africa. Here we collected 
anthropometric, biochemical and lifestyle-related data for HIV-positive HAART naive (n =25) and HIV-
positive individuals on HAART (n = 50) patients (20–55 years old) at the Worcester Community Day 
Centre (CDC) (Worcester, Western Cape, South Africa) during 2014 and 2015. Subjects on HAART 
were further divided into two sub-groupings, i.e. first line (n = 25) and second line treatments (n = 25).  
Results: Our data reveal the relatively high prevalence of traditional, cardio-metabolic lifestyle risk 
factors in HIV-infected individuals. There was a relatively high prevalence of smoking, i.e. 88% for the 
HIV-positive HAART naive group and 27% for the HIV-positive group on HAART (P = 0.001), while 
more than half of the HIV-positive individuals exhibited a positive history of familial cardiovascular 
diseases (CVD). There were no significant differences for fasting blood glucose (FBG) and insulin levels 
between HIV-positive HAART naive and HIV-positive on HAART. Lipid metabolite analyses (Total 
cholesterol [TC], low-density lipoprotein [LDL], high density lipoprotein [HDL] and triglyceride [TG]) 
also did not reveal significant changes when comparing HIV-positive on HAART versus HIV-positive 
HAART naive groups. However, additional analyses (using established cut-off values for HDL, LDL) 
showed a significant difference in the proportion of individuals categorized with ‘’low HDL’’ status, i.e. 
68% for the HIV-positive HAART naive compared to 40% for the HIV-positive on HAART group (P = 
0.022).  HAART also enhanced anthropometric measures of  obesity,  with  significant  differences  for 
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weight gain, triceps skin fold (TSF), biceps skin fold (BSF), waist circumference (WC) and mid-upper 
arm circumference (MUAC) between the naive and HAART groups. This applied similarly for first and 
second line treatments. 
Conclusion: The study established the prevalence of several traditional lifestyle CVD risk factors in both 
HIV-positive naive and HIV-positive on HAART in the Cape Winelands region of South Africa. 
HAART enhanced several measure of weight gain and lipid profile, suggesting a restoration to health 
and well-being. However, there was a relatively high prevalence of obesity in the HIV-positive on 
HAART group (especially females) thus placing them at a greater risk for the onset of future cardio-
metabolic complications. We are unable to distinguish whether this risk is due to HAART or lifestyle-
related risk factors, and this question requires further investigation. The findings of this study indicate 
that clinicians should be attentive of lifestyle-related CVD risk factors in HIV-positive persons and make 
an effort to counsel patients to adopt improved lifestyle choices. 
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Agtergrond: Alhoewel hoogs-aktiewe antriretrovirale terapie (HAART) die oorlewing van menslike 
immuniteitsgebrek virus (MIV)-geïnfekteerde pasiënte beduidend verbeter, is daar toenemende kommer 
aangaande die ontwikkeling van ko-morbiditeite (o.a. kardio-metaboliese komplikasies) en mortaliteit.  
Alhoewel Suid-Afrika gebuk gaan onder die grootste aantal MIV-geïnfekteerde individue wêreldwyd, is 
daar ‘n relatiewe tekort aan data wat die potensiële verband tussen MIV infeksie, HAART en kardio-
metaboliese risiko/aanvang betref.  
Metodes: Hierdie dwarssnitstudie ondersoek dus die voorkoms van kardio-metaboliese risiko faktore in 
MIV-geïnfekteerde individue binne die Kaapse Wynland distrik van Suid-Afrika. Hier het ons 
antropometriese, biochemiese en lewensstyl-verwante data vir MIV-positiewe HAART naïewe (n = 25) 
en MIV-positiewe individue op HAART (n=50; 20-55 jaar oud) by die Worcester Gemeenskaps-
dagsentrum (Worcester, Weskaap, Suid-Afrika) gedurende 2014 en 2015 versamel. Pasiënte op HAART 
is verder verdeel in twee sub-groepe, nl. eerste linie (n = 25) en tweede linie (n = 25) behandeling.  
Resultate: Ons data het ‘n relatiewe hoë voorkoms van tradisionele, kardio-metaboliese lewensstyl 
risiko faktore onder MIV-geïnfekteerde individue onthul. Daar was ‘n relatiewe hoë voorkoms van rook, 
nl. 88% vir die MIV-positiewe HAART-naïewe groep en 27% vir die MIV-positiewe groep op HAART 
(P = 0.001), terwyl meer as helfte van die MIV-positiewe individue ‘n positiewe geskiedenis van 
oorerflike kardiovaskulêre siektes (KVS) getoon het. Daar was geen beduidende verskille in vastende 
bloedglukose (FBG) en insulienvlakke tussen MIV-positiewe HAART naïewe en MIV-positiewe 
pasiënte op HAART behandeling nie. Lipied metaboliet analise (Totale cholesterol [TC], lae-digtheid 
lipoprotein [LDL], hoë-digtheid lipoprotein [HDL] en trigliseriede [TG]) het ook geen beduidende 
veranderinge onthul toe MIV-positiewe op HAART vs. MIV-positiewe HAART naïewe groepe vergelyk 
is nie. Additionele analise (deur gebruik te maak van afsny-waardes vir HDL, LDL) het egter beduidende 
verskille aangetoon in die proporsie individue gekategoriseer met “lae HDL” status, nl. 68% vir MIV-
positiewe HAART naïewe pasiënte, in vergelyking met 40%  vir  MIV-positiewe  pasiënte  op  HAART
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(P = 0.022). HAART het ook die antropometriese mate van vetsugtigheid verbeter, met beduidende 
verskille in massa-toename, triseps velvou (TSF), biseps velvou (BSF), middelmaat (WC) en mid-boarm 
omtrek (MUAC) tussen die naïewe en HAART groepe. Hierdie was soortgelyk vir eerste en tweede linie 
behandeling met HAART.   
Afleiding: Hierdie studie het die teenwoordigheid van verskeie tradisionele lewensstyl KVS risiko 
faktore in beide MIV-positiewe HAART-naïewe en MIV-positiewe op HAART bevestig in die Kaap 
Wynland distrik van Suid-Afrika. HAART het verskeie mates van massa toename en die lipied profiel 
verbeter, wat moontlike herstel van gesondheid en welwees aangedui het.  Daar was egter ‘n relatief hoë 
voorkoms van vetsug in die MIV-postiewe op HAART groep (veral vroulike pasiënte) wat hulle dus 
onder ‘n verhoogde risiko vir die ontwikkeling van toekomstige kardio-metaboliese komplikasies plaas. 
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1.0 Background  
The introduction of highly active antiretroviral therapy (HAART) over the last few decades has 
significantly modified the devastating effects of the human immunodeficiency virus (HIV) by 
prolonging survival and improving patients’ quality of life. In parallel, increasing cardio-metabolic 
complications have been documented since the introduction of HAART. Here early data established 
that HAART regimens (especially protease inhibitors [PIs]) are associated with increased metabolic 
(hyperlipidemia, insulin resistance [IR]) and somatic (lipodystrophy/lipoatrophy) (LD/LA) changes 
that are usually associated with a higher risk for cardiovascular diseases (CVD) (typically coronary 
and peripheral artery disease, strokes). Antiretroviral (ARV) drug regimens can be associated with 
metabolic side-effects that include dyslipidemia, impaired glucose metabolism and abnormal body 
fat distribution that all increase CVD risk. Compounding this problem is the HIV itself where 
persistent low-grade inflammation can also contribute to a higher incidence of cardio- and 
cerebrovascular events. Thus improved evaluations of metabolic status in HIV-positive individuals 
may assist with treatment modalities and enhance overall patient well-being by lowering co-
morbidities such as CVD in this instance. Of concern, however, are rising lifestyle-related disease 
onset e.g. the cardio-metabolic syndrome (CMS) in sub-Saharan Africa that together with HIV 
constitutes a double burden of disease. This chapter introduces ARV-mediated metabolic 
dysregulation and its impact on CVD risk in HIV-positive individuals, with a particular focus on the 
African continent and the South African context.  
 
1.1 HIV in Africa  
HIV infects 36.9 million people worldwide (UNAIDS 2014). The World Health Organization 
(WHO) estimated that acquired immune deficiency syndrome (AIDS) claimed about 2 million newly 
infected people at the end of 2014. Here sub-Saharan Africa remains the most severely affected with 
25.8 million persons saddled with HIV (Figure 1), representing ~70% of the globally afflicted 
population (UNAIDS 2014). For example, for three sub-Saharan countries (Nigeria, Uganda, South 
Africa) there were 1.4 million new HIV infections and 790, 000 deaths in 2014 due to AIDS-related 
causes (UNAIDS 2014). South Africa has the highest number HIV-positive individuals in the world, 
with 6.19 million persons being infected. These alarming numbers require robust interventions to 
counter the devastating effects of HIV and this may for e.g. include:  
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a) Educational programs to decrease new HIV infections 
b) Improvement of heath care systems in the region, providing ARV treatment and 
rehabilitating HIV-positive individuals   
c) Support HIV patients to better cope with HIV /AIDS-related illness and death.  
HIV type 1 and HIV type 2 are two distinct viruses, with type 1 the predominant one on a global 
scale. The HIV-1 strains can be classified into four groups (Hemelaar 2012), with ‘’M’’ (for ‘major’) 
the most important group and greatly responsible for the global HIV epidemic. Within group M there 
are known to be at least nine genetically distinct subtypes of HIV-1, i.e. subtypes A, B, C, D, F, G, 
H, J and K. The dominant HIV subtype in the Americas, Western Europe and Australasia is subtype 
B. However, this subtype represents only ~12% of global HIV infections.  By contrast, less research 
is available for subtype C although just under half of all persons living with HIV carry this particular 
subtype C. It is very common in the high prevalence countries of Southern Africa as well as in the 
African ‘’horn’’ and countries such as India (Fox et al. 2010; Hemelaar 2012). 
 
 
 
 
 
 
 
 
Figure 1: Persons living with HIV/AIDS in sub-Saharan Africa (UNAIDS 2014). 
 
 
The advent of HAART changed the nature of AIDS from a terminal, fatal illness to a chronic disease 
(Mutimura et al. 2008). This is supported by recent statistics (UNAIDS 2014) that showed a 
significant decrease in mortality rates with 1.2 million versus 2.3 million deaths worldwide in 2014 
and 2005, respectively. This represents a 42% decline in the mortality rate, in sub-Saharan Africa 
with HAART clearly prolonging life expectancy.  
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1.2 South Africa’s health care system and the issue of HIV 
South Africa is considered as an upper-middle income, multi-ethnic country and has an estimated 
population of 54 million people, with 11 official languages (23% Zulu-speaking, 16% Xhosa-
speaking, 14% Afrikaans-speaking, 9.6% English-speaking, 8% Setswana-speaking, 7.6% Sesotho-
speaking, with the residual official languages less than 5%) (Statistics South Africa 2012; The 
Economist 2011). In South Africa there are two types of health care systems (public, private) with 
80% of the population dependent on the public health sector with the rest relying on private health 
care. Due to the HIV/AIDS epidemic in South Africa the government is making a concerted effort to 
roll out ARV treatment. Here ARV treatment roll-out increased from 1.2 million in 2011 to 2.6-
million by 2014, making South Africa the largest country with programmed HIV treatment in the 
world (Media Club South Africa 2015). 
 
1.2.1 HIV in South Africa  
According to Statistics South Africa (2014; 2015), the total number of persons living with HIV 
increased from 4.02 million in 2002 to 6.19 million in 2015; this means that 11.2% of the South 
African population is HIV-positive. KwaZulu-Natal is one of the most affected regions, with about 
a third of the population being HIV-positive. In addition, women at reproductive age are mostly 
affected, e.g. about one-fifth of South African women are HIV-positive. With ARV treatment the 
total number of deaths decreased from 3.6 million (2005) to 1.7 million (2014), while new HIV 
infections declined from 5.4 million (2004) to 3.7 million (2012). With the expansion of the ARV 
roll-out, 2.2 million South Africans are currently receiving ARV treatment (Statistics South Africa 
2014).  Moreover, during December 2012 the Minister of Health announced the introduction of the 
fixed dose combination (FDC) of ARV triple therapy (to start April 2013).  Drugs employed in the 
FDC (TDF, FTC/3TC and EFV) were selected in order to improve access to antiretroviral treatment 
(ART) and to also increase the adherence and retention of patients on treatment (National Department 
of Health 2014).  
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1.2.2 HIV and AIDS treatment in South Africa   
As South Africa has the largest ART roll-out globally (The South African Antiretroviral Treatment 
Guidelines 2013), the expected benefits of the program were: 
 Increased life expectancy and quality of life for HIV patients 
 Cost-efficient treatment and improved clinical outcomes  
 Early HIV diagnosis by providing free testing 
 Decreased HIV/AIDS-related deaths 
 Prevention of new infections among children, adolescents, and adults.   
According to Meintjes et al. (2014), ARV treatment should commence in all HIV-positive patients 
who display a cluster of differentiation 4 T lymphocyte (CD4 T cell) count of ≤ 500 cells/mm3 and 
WHO clinical stages 3 or 4. There are three main treatment approaches:   
The first line treatment includes the use of two nucleoside reverse transcriptase inhibitors (NRTIs) 
and one non-nucleoside reverse transcriptase inhibitors (NNRTIs) in different regimens in the 
following possible combinations: 
- Tenofovir TDF +  Lamivudine 3TC/Emtricitabine FTC + Efavirenz EFV/Nevirapine NVP 
- Stavudine d4T + Lamivudine 3TC + EFV Efavirenz/Nevirapine NVP (for the new 
recommendation change d4T to TDF (no patient must be on d4T even if it is well tolerated) 
- Zidovudine AZT + Lamivudine 3TC + EFV Efavirenz/Nevirapine NVP. 
The recommended doses for first line treatment are indicated in Table 1. 
However, if side-effects or resistance develop then the second line of treatment is initiated – where 
viral load persists above 1,000 copies/ml. A boosted PI plus two NRTIs are then recommended for 
the second line of treatment:  
- Tenofovir TDF + Lamivudine 3TC/ Emtricitabine FTC + Lopinavir/ritonavir (LPV/r) 
- Zidovudine AZT + Lamivudine 3TC + LPV/r  
The recommended dose for LPV/r is LPV 200 mg/r 50mg given as 2 tablets twice daily (LPV 400 
mg/r 100 mg). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
23 
 
Table 1: The recommended doses for first line treatment in South Africa. 
Drug Dose 
Tenofovir (TDF) 300 mg daily 
Lamivudine (3TC) 300 mg daily 
Emtricitabine (FTC) 200 mg daily 
Efavirenz (EFV) 600 mg at night 
Nevirapine (NVP) 200 mg daily x 14 days, then 200 mg twice daily 
Zidovudine (AZT) 300 mg twice daily 
Stavudine (d4T) 30 mg twice daily (discontinued usage) 
 
The third line of treatment (salvage) is usually employed when there is resistance and virological 
failure for NRTIs, NNRTIs and PIs classes. Recently a number of new drugs in third-line ART has 
emerged and these include: a) integrase inhibitors, b) second generation of NNRTIs and PIs and c) 
chemokine co-receptors antagonists (CCR5) (Meintjes et al. 2014). 
 
1.3 The ABCs of ART 
1.3.1 Development of treatment strategies 
Since HIV was identified as the causative agent for AIDS a concerted effort has been made to develop 
medications that inhibit HIV replication. For example, the Food and Drug Administration (FDA) 
approved the first zidovudine (first ARV drug; NRTI) 28 years ago and this advance dramatically 
reduced the number of opportunistic AIDS related diseases and mortalities (UNAIDS 2011). 
Reverse-transcriptase inhibitors may also be non-nucleoside based and are referred to as NNRTIs. 
Both forms are commonly identified as reverse-transcriptase inhibitors (Batterham et al. 2001). Until 
the mid-1990s zidovudine and a number of other nucleoside analogues were the only available ART 
(Batterham et al. 2001). The NRTIs were initially employed as mono therapy, but later used as a dual 
combination. Although usage of such agents increased CD4 T cell counts, the first dose involved 
high drug toxicity. Furthermore, continued use triggered viral resistance and thus limited length of 
treatment and efficacy of such therapeutic agents (Barlett 1996). By the mid-1990s there was 
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widespread availability of viral load testing and the introduction of PIs, a new ARV drug class that 
inhibit the protease enzyme responsible for producing the mature virus (Lewin et al. 1997). LPV/r 
(Alluvia®) (Kaletra®) is a co-formulation of two structurally related PI ARV agents. LPV® is a 
highly potent and selective inhibitor of the HIV type 1 (HIV-1) protease, the enzyme responsible for 
production of the mature, infective virus. It acts by arresting maturation of HIV-1 and thereby 
blunting its capacity to infect and hence the main antiviral action of LPV is to prevent subsequent 
infections of susceptible cells (Cvetkovic & Goa 2003). Controlled trials of combinations containing 
PIs as one of three initial agents resulted in the recommendation that the standard HAART regimen 
should contain three ARV agents: two NRTIs plus PIs or two NRTIs plus an NNRTI (Carpenter et 
al. 1997) (refer Figure 2 for ARV time line). Recent data show that viral suppression following 
HAART results in decreased HIV transmission at individual (Cohen et al. 2011) and population 
levels (UNAIDS 2011). Moreover, HAART may provide protection against HIV infection when used 
consistently by HIV-uninfected persons (Grant et al. 2010; Baeten 2011; Thigpen et al. 2011). 
Together these developments have raised optimism regarding the HIV threat and translated into 
newly articulated visions of the “beginning of the end of AIDS” (Thompson et al. 2012:387). 
 
Figure 2: Time line for FDA approval and the development of ARV drugs. This reflects monumental efforts to 
produce most effective ARVs, to improve prognosis of persons living with HIV and to decrease AIDS-related 
mortalities and opportunistic infections.  NRTIs were initially used as mono therapy and later employed in dual 
combination; the HAART regimen should contain three ARV agents: two NRTIs plus PIs or two NRTIs plus 
NNRTI. NRTI,NNRTIs-nucleoside and non-nucleoside reverse transcriptase inhibitors, PIs-protease 
inhibitors, Chemokine co-receptors inhibitors (CCR5Is), Integrase inhibitors, AZT- Zidovudine, ddi- 
Didanosine, d4T-Stavudine, 3TC- Lamivudine, RTV- Ritonavir, IDV- Indinavir, NVP- Nevirapine, EFV- 
Efavirenz, Ritonavi-(r,RTV), TDF-Tenofovir, FTC- Emtricitabine, MVC-Maraviroc,NVPXR- Nevirapine 
extended release, DTG-Dolutegravir, EVG-Elvitegravir, ATV- Atazanavir, COBI- cobicistat. 
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1.3.2 ARVs - classes and characteristics 
The aim of ARV treatment is to achieve and sustain a plasma viral load that is undetectable 
(Batterham et al. 2001). ARV treatments are classified according to their inhibitory effects in 
different stages of the HIV life cycle (Figure 3). The main classes of ARV therapy are: 
1) NRTIs 
2) NNRTIs 
3) PIs 
4) CCR5 
5) Fusion inhibitors 
6) Integrase inhibitors 
7) Maturation inhibitors 
 
 
Figure 3: HIV life cycle and inhibitory action of ARVs. 1. Binding of HIV to receptors onto CD4 surface.    2. 
Fusion of HIV envelope to CD4 cell membrane. 3. Reverse Transcription of HIV genetic material; HIV-RNA 
is converted to DNA by reverse transcriptase. 4. Integration of HIV-DNA into host DNA by action of integrase. 
5. Transcription and translation - use host cell machinery to synthesize long chains of HIV-proteins. 6. 
Assembly - HIV-protease enzyme cleaves long chains of HIV-proteins to smaller proteins that when combined 
with HIV-RNA form new virus. 7. Budding - the newly formed HIV pushes out or ‘’buds’’ from the CD4 cell. 
HAART can inhibit at critical steps during HIV life cycle. NRTI, NNRTIs-nucleoside and non-nucleoside 
reverse transcriptase inhibitors, PIs-protease inhibitors, Entry inhibitors (Chemokine co-receptors inhibitors 
(CCR5Is)), DNA-deoxyribonucleic acid, RNA-ribonucleic acid, HIV-human immunodeficiency virus. 
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HAART regimens consist mainly of two or three drugs (from different classes) and typical regimens 
combine two NRTIs with NNRTI or PIs. Here treatment with triple combination regimens decreased 
AIDS-related morbidity and mortality (Hogg et al. 1998) (refer Table 2 for three main ARV classes). 
 
Table 2: Three main ARV classes. 
 
 
 
 
 
 
 
 
 
 
1. NRTIs and NNRTIs – mechanism of action   
After fusion of the HIV envelope with the host cell membrane, the uncoating of viral core 
occurs followed by slow release of the viral genetic material (RNA genome) and associated 
enzymes into the host cell cytoplasm. Reverse transcriptase then copies the viral single-
stranded RNA genome into a double-stranded viral DNA (reverse transcription and pro-viral 
DNA synthesis start). The viral DNA is then integrated into the host chromosomal DNA, 
which then allows the host cell to start both transcription and translation to produce new 
viruses. Reverse transcriptase (RT) was the first HIV enzyme that was targeted for ARV drug 
development. RT is a multifunctional enzyme with RNA-dependent DNA polymerase 
activities used to convert the single-stranded viral RNA to double-stranded DNA (Hu & 
Hughes 2011). RT is a target for two classes of ARV drugs, i.e. NRTIs and NNRTIs.  NRTIs 
must be activated in the cell by addition of three phosphate groups to their deoxyribose end to 
form NRTI triphosphates that are then able to incorporate into the viral DNA. NRTIs block 
the function of reverse transcriptase and prevent completion of synthesis of double-stranded 
NRTIs NNRTIs PIs 
Zidovudine® (ZDV, AZT) Nevirapine (NVP) Nelfinavir (NFV) 
Lamivudine® (3TC) Efavirenz (EFV, EFZ) Ritonavir (RTV) 
Stavudine® (d4T) Delavirdine (DLV) Saquinavir (SQV) 
Didanosine (ddi) Etravirine (ETV) Indinavir (IDV) 
Abacavir (ABC)  Lopinavir/ritonavir (LPV/r) 
Tenofovir (TDF)  Atazanavir (ATV) 
Emtricitabine (FTC)  Amprenavir (APV) 
Zalcitabine (ddc)  fos-Amprenavir (fos-APV) 
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viral DNA. This process is termed chain termination and stops the synthesis of viral DNA, 
thereby preventing HIV from multiplying. NNRTIs act by non- competitively binding to RT 
that leads to conformational changes that inhibit the catalytic activities of the enzyme, resulting 
in inhibition of transcription of the viral RNA and an attenuation of the replication rate 
(Imamichi 2004).   
  
2. PIs – mechanism of action 
HIV protease is responsible for a critical step during the HIV life cycle, i.e. the proteolytic 
cleavage of polypeptide precursors into mature enzymes and structural proteins. PIs are 
peptide-like chemicals that competitively inhibit the action of HIV protease. Such drugs inhibit 
proteolytic cleavage of HIV Gag and poly proteins which are important structural and 
enzymatic components of the new virus and thus prevents conversion of HIV particles into the 
mature virus (Debouck 1992; Imamichi 2004).   
 
1.4 HAART and the onset of cardio-metabolic complications 
HAART significantly improved outcomes of virological and the immunological tests (Hogg et al. 
1998) and the quality of life of HIV-positive patients (Liu et al. 2006). However, HAART (especially 
PIs) can also be associated with unfavorable metabolic disturbances such as dyslipidemia, impaired 
glucose tolerance (IGT), body composition changes and hypertension (HTN) (Dolan et al. 2005). 
Such complications are of course well-known CVD risk factors in the general population and hence 
also puts HIV-positive individuals at risk (Assmann et al. 2007). Because of such side-effects there 
are ongoing research endeavors to gain improved insights into risk factors and its impact on the well-
being of HIV-positive individuals, e.g. to ascertain whether these are similar or not compared to the 
general population (Mutimura et al. 2008). This is an ongoing and relatively recent process and here 
efforts are focusing on various metabolic, cardiovascular and anthropometric changes and how these 
intersect with more traditional risk factors (such as smoking, obesity) in HIV-positive persons 
(Figure 4). 
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Traditional 
risk factors 
(smoking, 
obesity,
HTN, DM)
HAART-     
specific
ARV
HIV
Insulin resistance 
↑Glucose
Dyslipidemia 
↑TG
↓HDL
↑FFABody composition 
lipoatrophy 
lipohypertrophy
Inflammation
CVD
 
Figure 4: Summary of the effects of HIV, HAART and traditional risk factors on CVD risk. CVD linked to the 
metabolic, anthropometric, inflammatory changes caused by HIV infection and HAART and intersection of 
traditional risk factors. TG- Triglyceride, HDL- High density lipoprotein, FFA- Free fatty acids, HTN- 
Hypertension, DM- Diabetes mellitus, CVD- Cardiovascular diseases. 
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1.4.1 Metabolic complications 
Effective treatment of HIV infection requires three or four drug regimens. However, as earlier 
discussed this can be associated with adverse side-effects (Schiller 2004) (Table 3). 
 
Table 3: Major adverse effects of HAART by drug class and organ system. 
System PI NRTI NNRTI 
Gastrointestinal 
Diarrhoea, nausea, vomiting (NFV) (Drugs 
for HIV infection 2009; Dubé et al. 2003; 
Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2011). 
Pancreatitis, anorexia, nausea, vomiting, 
non-cirrhotic portal hypertension (ddI) 
(Drugs for HIV infection 2009; Panel on 
Antiretroviral Guidelines for Adults and 
Adolescents 2011). 
Severe hepatotoxicity, liver failure (NVP) 
(Drugs for HIV infection 2009; Etravirine 
(Intelence) for HIV infection 2008; Panel on 
Antiretroviral Guidelines for Adults and 
Adolescents 2011). 
Neurologic 
Perioral paresthesia (fos-APV), circumoral 
and peripheral paresthesia (RTV) (Drugs 
for HIV infection 2009; Dubé et al. 2003; 
Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2011). 
Peripheral neuropathy, retinal changes, 
optic neuritis, (d4T, ddI) (Drugs for HIV 
infection 2009; Panel on Antiretroviral 
Guidelines for Adults and Adolescents 
2011). 
Dizziness, insomnia, headache, inability to 
concentrate, (EFV), peripheral neuropathy 
(ETV) (Drugs for HIV infection 2009; 
Etravirine (Intelence) for HIV infection 
2008; Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2011). 
Metabolic 
Lipohypertrophy, glucose intolerance or 
diabetes mellitus (DM), IR, lipid disorders 
and change in fat distribution (fat 
redistribution) all are not class-specific) 
(Drugs for HIV infection 2009; Dubé et al. 
2003; Panel on Antiretroviral Guidelines 
for Adults and Adolescents 2011). 
Lactic acidosis, hyperlipidemia; glucose 
intolerance; DM (d4t) (Drugs for HIV 
infection 2009; Panel on Antiretroviral 
Guidelines for Adults and Adolescents 
2011). 
Increased cholesterol and triglyceride levels 
(ETV), LA (EFV)  when used with (d4T)  
(Drugs for HIV infection 2009; Etravirine 
(Intelence) for HIV infection 2008; Panel on 
Antiretroviral Guidelines for Adults and 
Adolescents 2011). 
Renal 
Kidney stones, renal insufficiency (IDV) 
(Drugs for HIV infection 2009; Dubé et al. 
2003; Panel on Antiretroviral Guidelines 
for Adults and Adolescents 2011). 
Renal toxicity, proteinuria, renal failure 
(TDF) (Drugs for HIV infection 2009; 
Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2011). 
- 
Immunologic and 
dermatological 
Rash (fos-APV, SQV), alopecia (IDV) 
(Drugs for HIV infection 2009; Dubé et al. 
2003; Panel on Antiretroviral Guidelines 
for Adults and Adolescents 2011). 
Hypersensitivity reaction (ABC) 
hyperpigmentation of oral mucosa and 
nail beds (ZDV) 
hyperpigmentation of palms and soles 
(FTC)  
(Drugs for HIV infection 2009; Panel on 
Antiretroviral Guidelines for Adults and 
Adolescents 2011). 
Hypersensitivity reaction (ETV) (Drugs for 
HIV infection 2009; Etravirine (Intelence) 
for HIV infection 2008; Panel on 
Antiretroviral Guidelines for Adults and 
Adolescents 2011). 
  
Abbreviations: ddI = didanosine, NVP = nevirapine, NFV = nelfinavir, d4T = stavudine, EFV = efavirenz, TDF = tenofovir 
disoproxil fumarate, IDV = indinavir, ABC = abacavir, fos-APV = fos-Amprenavir, SQV= Saquinavir, RTV = Ritonavir, 
ZDV = Zidovudine, FTC = Emtricitabine, ETV = Etravirine. 
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The prevalence of metabolic (DM, IR, dyslipidemia) and phenotypic (abnormal fat distribution or 
LD syndrome) changes in HIV patients on HAART are on the increase (Barbaro 2006) and 
characteristics of metabolic syndrome (MetS) (Biron et al. 2012). There is increasing concern that 
metabolic disturbances associated with HIV and HAART may lead to increased risk for CVD. In 
support, the prevalence of MetS in HIV patients range between 11-45% and associated with a higher 
risk of developing CVD (Biron et al. 2012; Feleke et al. 2012; Jacobson et al. 2006). 
 
1.4.1.1 HAART and the MetS 
MetS is defined as a cluster of risk factors that include central obesity, dyslipidemia (high levels of 
triglyceride [TG], low levels high density lipoprotein [HDL]), abnormal glucose tolerance, IR and 
HTN (Reaven & Banting 1988), all that directly increase the risk for CVD and type 2 DM (T2DM) 
onset. There are many international organizations and expert groups such as the WHO clinical criteria 
(WHO 1999), the National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATP 
III) and the International Diabetes Federation (IDF) that have attempted to criteria that constitute the 
MetS. Here the basic premise is that the cluster of factors but an individual at even greater risk for 
CVD and T2DM onset compared to when such factors present independently (Bonora et al. 1998) 
(Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
31 
 
Table 4: The definition of the MetS by different criteria.  
WHO clinical criteria 
ATP III clinical criteria (NCEP 
Expert Panel 2001) 
IDF clinical criteria 
The individual must present with IGT, 
or DM, and /or IR with two or more of 
the following:  
- IGT or diabetes  
-IR (under hyperinsulinemic 
euglycemic conditions, glucose 
uptake below lowest quartile for 
background population under 
investigation)  
- Raised arterial pressure ≥ 140/90 mm 
Hg  
- Raised plasma TG (≥ 1.7 mmol/L; 150 
mg/dL) and/or low HDL cholesterol 
(< 0.9 mmol/L, 35 mg/dL men; < 1.0 
mmol/L, 39 mg/dL women)  
- Central obesity (males: WHR > 0.90; 
females: WHR > 0.85) and/or BMI > 
30 kg/m2 
- Microalbuminuria (urinary albumin 
excretion rate ≥ 20g/min or albumin: 
creatinine ratio ≥ 30 mg/g)  
 
Risk factor Defining level 
Individuals present with central obesity 
(with ethnicity-specific cut-off values, 
[Appendix 6]) plus two of the other factors  
Central 
obesity 
 WC 
• Men  
• Women 
> 102 cm (> 40 in)  
> 88 cm (> 35 in) 
TG 
≥ 150 mg/dL (1.7 
mmol/L) 
Increased 
TG levels 
≥ 150 mg/dL (1.7 mmol/L), 
or specific treatment for this 
lipid abnormality 
HDL 
cholesterol  
• Men  
 
• Women 
 
 
< 40 mg/dL (1.03 
mmol/L)  
< 50 mg/dL (1.29 
mmol/L) 
Reduced 
HDL 
cholesterol 
levels 
< 40 mg/dL (1.03 mmol/L)* 
in males and < 50 mg/dL 
(1.29 mmol/L)* in females, 
or specific treatment for this 
lipid abnormality 
Blood 
pressure  
≥ 130/ ≥ 85 mm Hg 
Raised 
blood 
pressure 
systolic BP ≥ 130 or 
diastolic BP ≥ 85 mm Hg, or 
treatment of previously 
diagnosed hypertension 
FBG 
≥ 110 mg/dL (6.1 
mmol/L)  
Elevated 
fasting 
blood 
glucose 
(FBG) 
levels 
(FBG) ≥ 100 mg/dL (5.6 
mmol/L), or previously 
diagnosed T2DM 
Three or more of the above five risk 
factors 
If above 5.6 mmol/L or 100 mg/dL, OGTT 
is strongly recommended but is not 
necessary to define presence of the 
syndrome. 
*These values have been updated from 
what were originally presented in order to 
ensure consistency with ATP III cut points 
(IDF 2006). 
 
Abbreviations: IGT = impaired glucose tolerance, DM = diabetes mellitus, IR = insulin resistance, TG = triglyceride, 
HDL = high density lipoprotein, WHR = waist-to-hip ratio, BMI = body mass index, WC = Waist circumference, FBG = 
fasting blood glucose, OGTT = oral glucose tolerance test. 
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- HAART and the prevalence of the MetS in Africa 
Many studies have reported the occurrence of MetS in the context of HIV/ AIDS and HAART 
and that this phenomenon is more common than in HIV-negative individuals (Bruno et al. 
2002; Gazzaruso et al. 2002; Palella et al. 2006) (Table 5). 
 
Table 5: HIV/HAART and MetS: African studies.  
Authors 
Number of 
participants 
HAART use Outcomes 
Sales et al. (2009) in 
Botswana. 
402 No (naive) 
The prevalence of MetS (7.7%)  in this cohort 
is similar to other sub-Saharan African HIV-
positive ones 
(Mhlabi 2011) in 
Botswana. 
190 Yes 
Prevalence of MetS was 11% and the most 
significant risk factors were being on NRTIs 
and PIs containing regimens 
Botha et al. (2013) in 
North-West province of 
South Africa  
66 on HAART, 
71 naive 
Yes 
Increase in pulse and systolic blood pressure 
together with an unfavorable lipid profile 
Berhane et al. (2012) in 
South West Ethiopia 
313 Yes 
21.1% MetS prevalence rate LD affecting 
12.1% of HIV-positive patients on HAART 
Diouf, et al. (2012) in 
Senegal 
242 Yes 
High prevalence of DM and HTN in 
Senegalese HIV-positive patients receiving 
HAART 
Muhammad et al. 
(2013) in Nigeria 
200 (100 on 
HAART, 100 
HAART‑naive) 
Yes 
Significantly higher prevalence of HTN, 
obesity and MetS among HIV-positive 
patients. 
McLigeyo et al. (2012) 
in Kenya 
265 patients Yes 
High prevalence of LD syndrome in HIV-
infected patients (51.3%) on chronic HAART, 
main phenotype was LA (44%) 
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Sales et al. (2009) determined the prevalence of MetS in a cohort of asymptomatic and ARV 
treatment- naive HIV-positive adults in Botswana and a prevalence of 7.7% was documented, 
together with high relatively percentages for obesity (11.6%) and HTN (31.9%). In support, 
another study in the same country (Mhlabi 2011) reported a similar prevalence of MetS (11%) 
and that the most significant risk factors were being on NRTIs and PIs therapeutic regimens. 
A study completed in the North-West province concluded that South Africans receiving 
HAART have a greater increase in pulse pressure, systolic blood pressure together with an 
unfavorable lipid profile versus normal controls (Botha, et al. 2013). However, whether long-
term HAART will lead to increased arterial stiffness and/or accelerated atherosclerosis in this 
instance remains unknown. Similar trends were reported for the rest of the African continent. 
For example, others found a 21% prevalence of the MetS in South West Ethiopia with LD 
affecting 12% of HIV-positive patients on HAART Berhane, et al. (2012). A similar scenario 
exists for Senegalese HIV-positive patients receiving HAART with high prevalence of DM 
and HTN in this population (Diouf, et al. 2012). This study confirms the association between 
the duration of HAART and DM and further highlights the need to implement preventative 
programs to reduce CVD risk factors in HIV-positive patients. Furthermore, Muhammad et al. 
(2013) reported that HAART is associated with a significantly higher prevalence of HTN, 
obesity and MetS among HIV-positive patients in Nigeria, while McLigeyo, et al. (2012) 
reported a high prevalence of LD syndrome (51%) in HIV-infected with LA the main 
phenotype. 
 
1.4.1.2 Dyslipidemia associated with HAART  
With prolonged HIV infection there are increased manifestation of metabolic side-effects such as 
hypertriglyceridemia (Feeney & Mallon 2011; Grunfeld et al. 1989). However, some may present at 
an earlier stage, e.g. dyslipidemia and IR can occur shortly after HAART initiation (Carr et al. 1998a; 
Feeney & Mallon 2011). Increased TG and low-density lipoprotein (LDL) cholesterol levels together 
with decreased HDL cholesterol levels are the most common lipid changes associated with 
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HIV/HAART (Fontas et al. 2004; Friis-Moller et al. 2003a; Friis-Moller et al. 2003b) and show 
overlap with the MetS (Grundy et al. 2004). In support, PIs lead to significant hypertriglyceridemia 
(Mulligan et al. 2000) and low HDL-C (Periard et al. 1999; Riddler et al. 2003), a strongly athrogenic 
pattern (Mercie et al. 2000). This is associated with increased risk for myocardial infarction (MI) in 
HIV-infected patients (Currier et al. 2003; Holmberg et al. 2002; Passalaris et al. 2000). HDL can 
inhibit the expression of E-selectin or other adhesion molecules by vascular endothelial cells exposed 
to cytokines and this results in decreased binding of inflammatory cells, which is consistent with 
functional inhibition of atherosclerosis (Moudry et al. 1997). Furthermore, supportive evidence for 
such HDL-mediated anti-atherogenic mechanisms is available from clinical studies where increased 
levels of adhesion molecules correlated with low HDL-cholesterol levels (Calabresi et al. 2002; 
Hernandez et al. 2003; Lupattelli et al. 2003). NNRTI-based regimens are also associated with 
decreased HDL levels (40% of HIV-positive individuals) together with increased total cholesterol 
(TC), LDL-C and TG levels. For example, EFV or NVP (commonly prescribed NNRTIs) treatment 
or both used in combination together with two NRTIs (d4T and 3TC) resulted in higher TG levels in 
the EFV arm compared to the NVP one (49% versus 20% at 48 weeks) (van Leth et al. 2004). Some 
NRTIs agents such as d4T is more tightly associated with dyslipidemia than others such as TDF 
(Gallant et al. 2004). Of note, the nature of such increases are less pronounced compared to the effects 
of PIs (Haubrich et al. 2009). 
 
- HAART-mediated dyslipidemia: pathophysiologic mechanisms 
The pathogenesis of dyslipidemia in this instance is complicated and includes several factors 
such as the effects of different drug classes, HIV itself, genetic predisposition, immunological 
and hormonal influences (Fisher et al. 2006; Guardiola et al. 2006). In addition, traditional risk 
factors (e.g. male sex, age, increased BMI, family history of CVD) and sedentary lifestyle) 
also affect pathogenic mechanisms that can contribute to HAART-induced dyslipidemia. 
There are three possible causes for increased plasma TG-rich very low density lipoprotein 
(VLDL) levels: decreased catabolism of VLDL by HIV infection itself (Carpentier et al. 2005); 
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increased production of such particles by HAART (Carpentier et al. 2005), or decreased 
catabolism of VLDL as a result of  PI effects (Shahmanesh et al. 2005).  HAART treatment 
reduces activity of plasma and tissue lipases that impair hydrolysis of TG-rich lipoproteins 
(Purnell et al. 2000; Reeds et al. 2006; Sekhar et al. 2005), disrupts  peripheral fatty acid (FA) 
uptake (van Wijk et al. 2005) and interferes with normal post-prandial lipoprotein and free 
fatty acid (FFA) catabolism (Reeds et al. 2006; van Wijk et al. 2005). Such detrimental effects 
may be mediated at the transcriptional level with transcriptional regulator sterol regulatory 
element binding protein 1 (SREBP1) a key regulator in this instance (Miserez et al. 2002). 
PI treatment leads to increased and abnormal accumulation of intramyocellular fat 
(Torriani et al. 2006) causing IR, while this further increases plasma TG-rich lipoproteins and 
apolipoprotein B (Beatty et al. 2004). PIs inhibit the intracellular proteasomal degradation of 
apolipoprotein B in hepatocytes thereby increasing secretion of apolipoprotein B-containing 
lipoproteins (Liang et al. 2001). Moreover, PI-mediated LD is linked with decreased 
expression of the LDL receptor (Petit et al. 2002) and related receptors (Reeds et al. 2003) and 
this leads to increased plasma LDL levels. 
Intracellular lipid metabolism changes are linked to the structural homology (about 
60% at the amino acid level) between the catalytic region of HIV protease and both LDL-
receptor-related protein type 1 (LRP1) and cytoplasmic retinoic acid-binding protein type 1 
(CRABP1) (Carr et al. 1998b). CRABP1 contributes to the conversion of retinoic acid to cis-
9-retinoic acid; this subsequently binds to the retinoid X receptor-peroxisome proliferator-
activated receptor γ (RXR-PPARγ), thereby activating adipocyte differentiation and inhibiting 
apoptosis (Carr et al. 1998b). PIs may bind to CRABP1 that prevents the formation of cis-9-
retinoic acid and resulting in decreased RXR-PPARγ activity and peripheral LA (especially 
gluteal region and the limbs) (Carr et al. 1998b). Ritonavir is a very strong inhibitor of the 
hepatic cytochrome P4503A4 enzyme (Acosta 2002) and this leads to a decrease in cis-9-
retinoic acid formation, lowering of RXR-PPARγ activity and thereby resulting in more LA 
and aggravated dyslipidemia (Carr et al. 1998b; Penzak & Chuck 2000). TG and LDL-C levels 
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increased by 26% and 16%, respectively, following two weeks of ritonavir treatment (Shafran 
et al. 2005). Moreover, when LPV/r is administered to HIV-negative subjects (4 weeks 
period), serum TG increases by 83%, FFA by 30% and VLDL-C by 33% (Lee et al. 2004a). 
PIs can also bind to LRP1 preventing formation of LRP1- lipoprotein lipase (LPL) 
complex and thus resulting in increased plasma TG levels and decrease storage capacity of 
adipose tissues (Zimmermann et al. 2001). LRP1 usually binds to LPL to inhibit its action (Hu 
et al. 2001). FFAs that cannot stored in adipocytes are taken up by the liver, stimulating hepatic 
synthesis of TG-rich lipoproteins and thereby causing more hypertriglyceridemia (Carr et al. 
1999). 
Another mechanism whereby HAART can contribute to dyslipidemia is mitochondrial 
dysfunction (Cossarizza et al. 2003), particularly with NRTIs in combination with PIs.  This 
occurs as a result of their ability to inhibit mitochondrial DNA polymerase γ, the enzyme 
responsible for replication of mitochondrial deoxyribonucleic acid (mtDNA) (Cote 2005). 
This can cause the depletion of mtDNA (Nolan et al. 2003; Shikuma et al. 2001) and also lead 
to attenuated mitochondrial ribonucleic acid (mtRNA) expression (Mallon et al. 2008). Such 
changes can occur within a relatively short period of time e.g. after two weeks exposure 
(Mallon et al. 2005), leading to respiratory chain dysfunction and decreased energy production 
(Cossarizza et al. 2003). Mitochondrial respiratory chain dysfunction causes defects in many 
cell types, e.g. in adipocytes it can cause LA (Cossarizza et al. 2003) while in skeletal muscle 
it leads to IR and by secondary dyslipidemia (Pinti et al. 2006). Metabolic abnormalities may 
also be caused by interactions between cellular proteases and PIs thereby altering 
mitochondrial function (Zaera et al. 2001). The proposed pathophysiological mechanisms of 
ARV-associated dyslipidemia are summarized in Table 6.   
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Table 6: ARV-associated dyslipidemia: pathophysiologic mechanisms. 
Mechanism Effect 
PIs 
 PIs bind to CRABP1 (60% homology 
between HIV-1 protease and CRABP1) 
Prevent activation of retinoic acid, decreasing PPAR-γ 
activity 
 PIs inhibit  Cytochrome P4503A4 Decrease amount of activated retinoic acid synthesized 
 PIs bind to the LDL-receptor-related 
protein-1 (LRP-1) 
Prevent binding of LRP1 binding to endothelial lipoprotein 
lipase, resulting in increasing plasma triglyceride and FFA. 
 Decreased lipid intake and increased 
lipolysis in adipocytes 
Increased plasma TG levels 
 PIs block the intracellular proteasome 
Decreased degradation SREBP1 leading to increased 
hepatic production of lipoprotein. 
 PIs lead to increased and abnormal 
accumulation of intramyocellular fat 
Elevated levels of TG, IR and apolipoprotein B 
 Inhibition of activated  retinoic acid 
Decreased PPAR-γ activity, inhibits adipocyte 
differentiation and increased apoptosis, FFA flux to the 
liver and skeletal muscle causing IR 
NRTIs 
 Mitochondrial dysfunction 
Inhibition of mitochondrial DNA polymerase γ, respiratory 
chain dysfunction, decreased energy production, LA and 
IR in skeletal muscle. 
  
1.4.1.3 Insulin resistance, altered glucose tolerance and diabetes 
IR occurs when target tissues fail to respond to insulin and hence higher insulin concentrations are 
required to achieve a normal metabolic response (Florescu & Kotler 2007). This leads to increased 
hepatic gluconeogenesis and decreased muscle glucose uptake, often resulting in high systemic 
glucose levels. The latter can occur even though there are relatively high insulin levels resulting in 
IGT followed by DM. An important method to measure IR and pancreatic β-cell function is the 
homeostatic model assessment (HOMA). This was initially defined in 1985 and is a mathematical 
calculation of β-cell function in response to glucose. However, the original model did not 
differentiate between peripheral and hepatic insulin sensitivity. An updated HOMA is currently 
employed to estimate IR and is based on fasting levels of plasma glucose and insulin, HOMA-IR can 
be calculated by using [Insulin (mU/L) × glucose (mmol/L)/22.5] (Henderson et al. 2011; Matthews 
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et al. 1985). Early diagnosis of IR is useful as it potentially allows for lifestyle change to be instituted 
in order to prevent development of T2DM (Matthews et al. 1985).  
HIV-infected patients in the pre-HAART era displayed different alterations in glucose 
metabolism compared to the HAART era. Additionally, there were increased rates of insulin 
clearance and sensitivity of peripheral tissues to insulin in the pre-HAART era (Florescu & Kotler 
2007; Hommes et al. 1991). Of note, the prevalence of IR, glucose intolerance and DM increased 
significantly following the introduction of HAART to HIV-positive individuals (Florescu & Kotler 
2007). Here IR is very common; e.g. about 50% of PIs-treated patients experience IR compared to 
25% for those on NRTIs therapy (DAD Study Group 2003). The definitions of impaired fasting 
glucose (IFG), IGT and DM are summarized in Table 7 (WHO 2006). 
 
Table 7: WHO recommendations for the diagnostic criteria for DM and intermediate hyperglycemia. 
IFG FBG 6.1 to 6.9 mmol/l (110 mg/dl to 125mg/dl) and 2–h blood 
glucose < 7.8 mmol/l (140 mg/dl) 
IGT FBG < 7.0 mmol/l (126 mg/dl) 
and 2–h blood glucose ≥7.8 and < 11.1 mmol/l (140 mg/dl and 
200 mg/dl) 
DM FBG ≥ 7.0 mmol/l (126 mg/dl) 
or 2–h blood glucose ≥11.1 mmol/l (200 mg/dl) 
Abbreviations: IFG = impaired fasting glucose, IGT = impaired glucose tolerance, DM = diabetes 
mellitus, FBG = fasting blood glucose.  
 
- Pathogenesis of HAART induced IR 
The cause of IR, glucose intolerance and DM is multifactorial in HIV-infected patients 
(Florescu & Kotler 2007). Pathogenic factors may be related to the HIV infection itself, its 
treatment, treatment–associated weight gain or immune restoration (Hommes et al. 1991). 
However, other pathogenic processes share similarities with non-HIV-infected individuals, 
e.g. increased FFA concentrations, visceral fat accumulation, increased muscle and organ fat, 
hormonal alterations, chronic inflammation, genetic factors and co-morbidities (Hommes et 
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al. 1991). PIs were initially considered the most likely cause of such conditions, e.g. early after 
its introduction (1996) IR, DM and LD manifested in such treated individuals. 
1- PIs-associated IR: Ritonavir and LPV were the first HIV medications linked to the 
pathogenesis of glucose abnormalities among HIV-infected patients (Samaras 2009). 
Moreover, subsequent research demonstrated that the risk for DM is dose- (Taylor et al. 2010) 
and duration-dependent and individual PIs display different capacities to induce IR (Capeau 
et al. 2012). When the PI treatment is discontinued, glycemic dysregulation normalizes in most 
patients (Lee et al. 2004b). The available evidence indicates that PIs can disturb glucose 
metabolism through different mechanisms: 
a) The down regulation of Glucose transporter type 4 (GLUT-4) that is responsible for the
transport of glucose into fat cells, skeletal and cardiac muscle (Rudich et al. 2005). 
b) Decreasing adipocyte differentiation due to inhibition of PPAR-γ (Lee et al. 2004b).
c) Saqunavir and ritonavir treatment lead to a 25-50% decrease in pancreatic β-cell
function, although mechanisms remain poorly understood; thus patients with DM 
receiving such drugs should be treated with insulin therapy rather than insulin 
sensitizing drugs (Kim et al. 2011). 
2- NRTIs-associated mitochondrial toxicity: NRTIs can cause mitochondrial dysfunction as 
it also inhibits DNA polymerase γ, the DNA polymerase playing an active role in 
mitochondrial replication (Lewis et al. 2003). By contrast, NNRTIs do not inhibit DNA 
polymerase-γ and hence do not lead to mitochondrial dysfunction. Such mitochondrial 
perturbations can lead to organ dysfunction, e.g. leading to lactic acidosis and steatosis in the 
liver. Additional factors that can affect mitochondrial function include oxidative stress and 
inflammation. The end result following mitochondrial dysfunction (depending on the degree 
of) is cell death by apoptosis (Gerschenson & Brinkman 2004). Of note, two NRTIs (TDF and 
ABC) are weak inhibitors of DNA polymerase γ and hence less toxic to mitochondria (Birkus 
et al. 2002; Cihlar et al. 2002; Gerschenson & Brinkman 2004). Figure 5 displays a summary 
of whereby ART can contribute to dyslipidemia and IR. 
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Figure 5: Pathophysiological mechanisms of ART-associated dyslipidemia and IR. The pathogenesis of dyslipidemia and IR is complex and includes effects of different drug classes, HIV itself, genetic 
predisposition, immunological and hormonal influences as well as traditional risk factors. PI class is mainly responsible for detrimental molecular changes underlying metabolic disturbances.  PIs bind to CRABP1 
preventing conversion of retinoic acid to cis-9-retinoic acid and decreased RXR-PPARγ activity leads to lowering of adipocyte differentiation and increasing apoptosis. In addition there is increased flux of FFA 
to the liver and skeletal muscle causing IR. PIs bind to the LRP-1 preventing binding of LRP1 to endothelial LPL and formation of the LRP1-LP complex resulting in increased plasma TG and FFA, decreased 
storage capacity of adipose tissues and stimulating hepatic synthesis of TG. PIs block the intracellular proteasome resulting in decreased degradation of SREBP1 and hence leading to increased hepatic production 
of lipoproteins. PIs inhibit Cytochrome P4503A4 resulting in decreased amounts of activated retinoic acid being synthesized. PIs inhibit GLUT4, leading to peripheral IR and impaired glucose tolerance. PIs lead 
to increased and abnormal accumulation of intramyocellular fat leading tolipidemia and IR. NRTIs can cause negative metabolic changes by their ability to inhibit mt DNA polγ leading to respiratory chain 
dysfunction, dyslipidemia and IR.  PIs-protease inhibitors, CRABP1- cytoplasmic retinoic acid-binding protein type 1, RXR-PPARγ- retinoid X receptor-peroxisome proliferator-activated receptor γ, FFA- free 
fatty acids, TG- triglyceride, LRP-1- LDL-receptor-related protein type 1, LPL- lipoprotein lipase, SREBP1- sterol regulatory element binding protein 1, GLUT4- glucose transporter 4, mt DNA polγ- 
mitochondrial DNA polymerase gamma, mit DNA- mitochondrial DNA.  
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1.4.1.4 HAART-associated morphological alterations/body shape changes 
The term LD (or fat redistribution syndrome) describes metabolic and stereotypical body disfiguring 
fat changes in HIV-infected patients receiving HAART. This syndrome is characterized by abnormal 
body fat redistribution and can present as a) peripheral fat wasting (LA) mainly in the face, limbs, 
and buttocks; and b) central fat accumulation in the abdomen, breast or posterior neck 
lipohypertrophy (LH); or a mixture of both. LD occurs in more than half of HIV-infected patients 
treated with HAART (Grunfeld et al. 2010; Jacobson et al. 2005) and here LA and LH are 
characterized by different risk factors that occur independently of each other despite the fact that 
such conditions  occurs together (FRAM 2006). Many researchers found that NRTI drugs (especially 
d4T) associated mostly with LA and here the underlining mechanism is mitochondrial dysfunction 
(Mallon et al. 2005; Nolan 2003). PIs and NNRTIs can also contribute, e.g.  PIs cause inhibition of 
adipocyte differentiation with subsequent LA (Kim et al. 2006; Zhang et al. 1999). The etiology of 
LH and ectopic fat accumulation is not clear but may related or caused either by high levels of 
inflammatory cytokines (Johnson et al. 2004) or elevated TG and FFA levels that cannot stored in 
atrophic subcutaneous fat tissues (Huang-Doran et al. 2010). A minority of HIV patients with LH 
also exhibit elevated serum and urine cortisol concentrations. However, there is appropriate 
suppression of cortisol levels in response to dexamethasone and normal diurnal variation in cortisol 
levels. 
For HIV-infected patients with fat redistribution syndrome there is more metabolic 
disturbances especially dyslipidemia and IGT compared to negative controls (Hadigan et al. 2001). 
Interestingly, HIV-positive positive men with LD syndrome display the similar interleukin 6 (IL6), 
C-reactive protein (CRP), tumor necrosis factor α (TNFα) and adiponectin levels as for obese HIV-
negative men (Samaras et al. 2009). Wohl et al. (2008) show that increased visceral fat and decreased 
subcutaneous leg fat are associated with elevated TG levels and attenuated HDL-C levels. Moreover, 
the Fat Redistribution and Metabolic Change in HIV (FRAM) cohort demonstrated that both 
peripheral LA and visceral LH are associated with an increased Framingham Risk Score (used to 
calculate absolute 10-year risk of MI or cardiac death) (Dube et al. 2003) and therefore  predictive 
of MI (Lake et al. 2011). For both peripheral fat atrophy and visceral fat accumulation there is 
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evidence of subclinical atherosclerosis and  studies confirmed that especially the latter is associated 
with progression of subclinical atherosclerosis (Guaraldi et al. 2012) as well as overall mortality 
(Scherzer et al. 2011) in HIV- infected patients. In addition, visceral adiposity (especially abdominal 
or central obesity) is associated with an increased risk of cardio-and cerebrovascular diseases as it is 
linked to numerous metabolic disturbances. For example, IR, dyslipidemia, IGT and HTN are all 
strong risk factors for CVD and premature death (Guzzaloni et al. 2009).  
The best methods to assess the volume of visceral adipose tissue (VAT) are computerized 
tomography (CT) scan and magnetic resonance imaging (MRI). However, such techniques are not 
readily available in all clinics and are very expensive especially within a developing world context 
(Kullberg et al. 2007; Van der Kooy & Seidell 1993). Visceral adiposity can also be estimated by 
waist circumference (WC) or sagittal abdominal diameter (SAD) measurements, both simple 
anthropometric measurements that were proposed as alternatives for evaluating body fat distribution 
(Nordhamn et al. 2000; Sampaio et al. 2007; Turcato et al. 2000).  
 
1.4.2 CVD   
CVD and especially coronary heart disease (CHD) are a major cause of mortality death with 
HIV/AIDS (Mathers & Loncar 2006). Here HIV-infected patients display increased CVD rates that 
likely occurs due to HAART-mediated side-effects and also by systemic, chronic inflammation due 
to the HIV itself (Subramanian et al. 2012). In addition, endothelial injury can be triggered by HIV 
itself (Torre 2006), the effects of HAART (De Lorenzo et al. 2008) as well as increased traditional 
CVD risk factors such as dyslipidemia, DM, smoking and HTN (Hsue et al. 2012).  Such risk factors 
may be associated with usage of specific ARV drugs (Amado & Ruiz 2007) and can all be predictors 
of cardiac events in such individuals (Ho & Hsue 2009) (Figure 6). 
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study (large prospective, 
multi-cohort study) confirmed an increased MI risk with ARV exposure (Friis-Moller et al. 2003a). 
Here there were a 26% increase in the MI rate per year of HAART exposure (Friis-Moller et al. 
2003a). Moreover, others found that HIV-positive individuals receiving HAART exhibited 
atherogenic lipid profiles (high TC, total TG and low levels of HDL cholesterol) compared to 
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HAART naive HIV-infected patients (Fontas et al. 2004). Table 8 summarizes the relationship 
between CVD risk factors and MI risk in HIV patients (DAD Study Group et al. 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 6: HIV/HAART induces lipodystrophy, dyslipidemia and IR and thus increases the risk of coronary 
heart disease and diabetes (adapted from Zou & Berglund 2007). 
  
 
Table 8: Relationship between CVD risk factors and the rate of MI in HIV patients. 
CVD risk factors Relative risk of heart attack P-value 
TC 1.26 (1.19-1.35) < 0.001 
HDL  0.65 (0.48-0.88) 0.05 
Diabetes 1.86 (1.31-2.65) < 0.001 
Current smoker 0.92 (2.04-4.18) < 0.001 
Former smoker 1.63 (1.07-2.48) 0.02 
Hypertension 1.30 (0.99-1.72) 0.06 
CVD family history 1.40 (0.92-1.91) 0.08 
Previous CVD event 4.64 (3.22-6.69) < 0.001 
Age per additional 5 years 1.32 (1.23-1.41) < 0.001 
PIs use per additional year 1.10 (1.04-1.18) 0.002 
BMI >30 1.34 (0.86-2.09) 0.19 
 
 
dyslipidemia 
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Insulin resistance Diabetes 
CHD 
Fat hypertrophy/atrophy 
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TT 
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1.4.2.1 CVD risk in HIV-positive individuals: contribution of metabolic dysfunction and 
traditional risk factors 
The risk of CHD in HIV patients is significantly affected by traditional factors (Savès et al. 2003) 
while metabolic complications (mainly PI- and NRTI-mediated dyslipidemia and IR) also play a role 
(Ho & Hsue 2009). It is important to consider two issues when evaluating the evidence implicating 
ARV-induced metabolic complications as factors for increased CVD risk. Firstly, early studies were 
performed in HIV-infected patients receiving only single or dual treatment, while in the second 
instance the new HAART regimens make it challenging to discriminate between the distinct effects 
of various drugs making up the treatment cocktail (Grunfeld et al. 2008). HIV-infected patients with 
acute coronary syndrome (ACS) display specific features when compared to non-HIV individuals, 
e.g. this population develops ACS at a relatively younger age with high prevalence of smoking and 
relatively low HDL levels. Moreover, they also show no clear abnormalities in their coronary arteries 
(by angiography) and arterial lesions exhibit specific histological features, e.g. are diffuse and rapid 
progression of circumferential arterial pathology with proliferation of elastic fibers, smooth muscle 
cells and endoluminal protrusions (Subramanian et al. 2012). 
 
1.4.2.2 HAART and HTN 
According to the WHO and International Society of Hypertension (ISH) guidelines hypertension is 
defined and diagnosed as displaying a mean systolic blood pressure (SBP) ≥ 140 mmHg and a 
diastolic blood pressure (DBP) ≥ 90 mmHg. Alternatively, with two or more clinic visits individuals 
display elevated BP while others exhibit normal values but receiving antihypertensive drugs 
(Whitworth 2003). As HTN is a well-known as a risk factor for CVD, greater understanding of the 
link between HAART and HTN is of primary importance. For example, many studies reveal that 
HTN is common in HIV-positive patients (Chow et al. 2003; Gazzaruso et al. 2003), although it was 
rare before HAART introduction. Dillon et al. (2013) performed a systematic review and meta-
analysis and found that individuals infected with HIV in sub-Saharan Africa displayed lower DBP 
and SBP than controls, regardless of ART status. Previous studies assessing the associations between 
HIV, ART and blood pressure have been inconsistent, with some suggesting increased risk of 
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hypertension with ART (Gazzaruso et al.  2003). By contrast, some reported no association with HIV 
or ART (Bergersen et al.  2003; Jerico et al.  2003) while others supported the findings of the meta-
analysis highlighted above (Schutte et al.  2012). 
There are numerous factors that may explain this phenomenon including a) an aging HIV-
positive population and thus appearance of usual HTN risk factors for development of HTN and b) 
direct effects elicited by HIV itself or HAART. For example, the D:A:D study established that  HTN 
in the HIV-positive population is related to traditional risk factors such as hyperlipidemia, age, black 
race, male gender, increased BMI and microalbuminuria (Friis-Moller et al. 2003b). However, 
further investigations are needed to better understand the link between ARV drugs and HTN as some 
mixed data have been generated thus far (Cattelan et al. 2001; Chow et al. 2003) (Table 9).  
 
Table 9: HIV ± HAART and the risk for hypertension.  
Author Outcome 
Medina-Torne et al. (2012) 
High prevalence of HTN (31%) related to the duration, immune 
activation and endothelial changes caused by HIV  
Boccara et al. (2010) 
Adipocyte dysfunction and activation of renin angiotensin system (RAS) 
caused by PI treatment 
 
For example, some found that HTN is common and correlated strongly with known risk factors but 
that it was not related to the use of HAART in HIV-positive patients (Medina-Torne et al. 2012). 
The authors indicated that the high prevalence of HTN is related to the duration of HIV-infection 
and that endothelial changes occurred due to the virus and immune activation. By contrast, Boccara 
et al. (2010) performed in vitro work on adipocytes incubated with LPV/r and found that such 
treatment induced adipocyte dysfunction and activation of renin angiotensin system (RAS). 
Moreover, others showed that duration of HAART and also PIs can increase the prevalence of HTN 
(Baekken et al. 2008; Seaberg et al. 2005). Here a link between LD and increased risk of HTN was 
consistently suggested (Baekken et al. 2008; Crane et al. 2009; Gazzaruso et al. 2003; Seaberg et al. 
2005; Thiebaut et al. 2005). These conflicting data there indicate that additional studies are required 
to fully ascertain the link between HIV and/or HAART and the onset of HTN in HIV-positive 
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individuals. Here careful attention should be paid to different models employed (if pre-clinical work) 
and also the nature of clinical studies, e.g. with all the necessary control groups and sufficient recruits 
included. 
 
1.4.2.3 Surrogate measures of atherosclerosis in HIV patient receiving HAART 
Surrogate measures of early atherosclerosis are useful clinically and include endothelial dysfunction 
and carotid intima–media thickness (IMT) - sensitive measures and predictors of future CVD events.  
Studies focusing on IMT and endothelial dysfunction showed that the risk of CHD increases with 
PIs (Hsue et al. 2004; Maggi et al. 2000; Meng et al. 2002; Stein et al. 2001). The virus itself has 
also been implicated, e.g. HIV infection can cause endothelial dysfunction (Bonnet et al. 2004) and 
carotid IMT (Hsue et al. 2004). Here HIV stimulates inflammatory pathways and this lead to the 
production of TNFα and β, nuclear factor-κβ, IL-6, vascular cell adhesion molecule (VCAM)-1, 
intracellular adhesion molecule (ICAM)-1, and endothelial cell adhesion molecule-1 (Fisher et al. 
2006). Subsequently, such chemokines can activate the atherosclerotic process and therefore increase 
the risk of an MI in this group of individuals (Fisher et al. 2006). 
 
Endothelial dysfunction 
Endothelial dysfunction is an early sign of atherosclerosis and it is a useful predictor of future 
CVD events (Davignon & Ganz 2004; Vita & Keaney 2002). There are many sensitive 
markers of endothelial dysfunction that include VCAM-1, ICAM-1, von Willebrand factor and 
thrombomodulin (Muller & Griesmacher 2000). These markers are usually elevated in persons 
with hyperlipidemia, HTN, DM, oxidative stress and a history of smoking (Cines et al. 1998). 
Markers for endothelial activation can be elevated in HIV-infected patients together with 
downstream effects such as the onset of a hypercoagulable state (Aukrust et al. 2000) (Cines 
et al. 1998). The latter can be monitored by measuring coagulation markers such as thrombin 
and anti-thrombin III. With thrombin production, activated endothelial cells produce adhesion 
molecules (Henn et al. 1998) and elicit an inflammatory reaction and atherosclerosis (Tsakiris 
et al. 1999). 
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HAART decreases (but does not normalize) immune activation and inflammatory 
cytokine levels in HIV-infected patients (Aukrust et al. 1999; Bisset et al. 1998), that can lead 
to a partial release of adhesion molecules (Moore et al. 1998; Sousa et al. 1999). The HAART-
mediated decrease in HIV replication and viral load should improve T-cell function and 
decrease endothelial dysfunction. In agreement, others noted a significant decrease in VCAM-
1 and ICAM-1 levels after the first months of HAART initiation. Such observations indicate 
that endothelial activation is mediated by HAART-mediated control of viral replication (Wolf 
et al. 2002). HAART may cause endothelial cell activation, e.g. HIV-positive  persons treated 
with PIs or NNRTIs presented with higher levels of P-selectin, tissue plasminogen activator 
(tPA), and plasminogen activator-1 (PAI-1) than in HIV-infected naive subjects and there was 
a positive relationship between endothelial markers and lipid levels (De Gaetano et al. 2003). 
It is suggested that HAART should reduce endothelial damage by controlling HIV infection, 
but associated, deranged lipid and glucose metabolism can also contribute to endothelial 
activation. Furthermore, HAART seems to directly induce endothelial activation, e.g. ritonavir 
and indinavir can cause endothelial dysfunction together with mitochondrial DNA damage and 
cell death (independently of lipid profile) (Dube et al. 2002; Zhong et al. 2002). In addition, 
for a large cohort study of HIV-infected patients the serum concentrations of PAI-1 were high 
in PI- treated and untreated patients with MetS and its level associated with PI use, insulin 
levels, TG levels and BMI (Koppel et al. 2002). These results show that HAART may cause 
atherosclerosis both by direct effects on endothelial cells and by indirect effects via metabolic 
derangements.  
 
Carotid intima-media thickness (IMT) 
HIV-infected individuals have a higher prevalence of CHD which can be measured by non-
invasive high-resolution ultrasound technique to assess IMT (representative of subclinical 
vascular disease and future CVD events) also found that HIV-infected persons display a higher 
CHD prevalence (Stein et al. 2008). Carotid IMT studies in the HIV-infected patients have 
yielded conflicting results, with high IMT caused by both HIV infection itself (Lorenz et al. 
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2008) and HAART related (Coll et al. 2006; Currier et al. 2007; Lebech et al. 2007; Lorenz et 
al. 2008). Some determined that IMT:IMT values were 24% more at the carotid bifurcation in 
HIV-infected individuals on HAART compared to controls and about 6% greater in the 
common carotid artery confirming that there are site-specific differences in IMT (Lorenz et al. 
2008). Moreover, vascular risk was increased by 4% to 14% in HIV-positive persons (Lorenz 
et al. 2008). However, there were no differences in IMT in non-smoking HIV-infected 
HAART recipients, irrespective of TC levels (Lebech et al. 2007). Currier et al. (2007) 
reported that there were no differences in the rate of progression of IMT over three years 
between HIV-infected subjects receiving PIs, those on non-PIs HAART, and uninfected 
controls (all matched for age, gender, ethnicity, smoking status and blood pressure). There is 
also a three-fold increase in carotid IMT in HIV-infected patients on HAART with LD 
syndrome and also for IMT-related levels of circulating monocyte chemo-attractant protein-1 
(Coll et al. 2006). There is also increased carotid artery IMT in HIV-infected patients on 
HAART with MetS (Mangili et al. 2007), while others with MetS also displayed significantly 
higher IMT and epicardial fat thickness (Iacobellis et al. 2007). In a three year prospective 
controlled study the progression of carotid IMT was linked to LDL-cholesterol and 
homocysteine levels but not to HIV-HAART (Currier et al. 2007). Carotid IMT has also been 
found to relate to epicardial fat thickness and visceral adipose tissue in HIV-infected patients 
on HAART. Metabolic changes are common in HIV infection/HAART have been associated 
with an increased IMT (Seminari et al. 2002). Together these studies demonstrate that it is 
important to establish the role of prolonged survival, age, traditional non-traditional risk 
factors with HIV/HAART in relation to surrogate markers of atherosclerosis. 
 
1.5 Problem statement 
Sub-Saharan African remains the most severely affected region with HIV/AIDS, with South Africa 
saddled with the highest number of HIV-positive positive individuals in the world. HAART has 
improved the prognosis of HIV-infected patients with clear decrease in the incidence of opportunistic 
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infections and transforming AIDS from an irreversible terminal illness to a chronic disease with 
improved quality of life. However, HAART regimens have been implicated in the development of 
metabolic complications (e.g. dyslipidemia, IR) and there is accumulating evidence of its link to 
elevated CVD onset. With the high prevalence of HIV/AIDS in South Africa, the extent and nature 
of cardio-metabolic complications in HIV-positive individuals remain relatively poorly understood.  
 
1.6 Research question 
To establish the prevalence of several cardio-metabolic complications in HIV-positive patients on 
HAART (first line versus second line) within the Cape Winelands region of South Africa. Such 
information should improve clinical management of HIV-positive patients within the region and help 
to enhance their overall health and wellbeing.  
 
1.7 Study objectives 
 To determine the prevalence of several cardio-metabolic risk factors in HIV patients within 
the Cape Winelands region (Community Day Centre (CDC) at Worcester Hospital, 
Worcester, South Africa) 
 To determine the association between anthropometrical parameters, smoking status and 
cardio-metabolic risk factors in this population group. 
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2.0 Introduction 
This chapter discusses the methods employed to obtain and analyze data. In addition, there is also a 
description of the study setting, population, sampling and the criteria for participation. Ethical 
consideration/approvals are also discussed. 
 
2.1 Study design  
This study forms part of a larger longitudinal study namely the ‘‘Cape Winelands HAART to 
HEART Study’’ within the Cape Winelands region of the Western Cape (South Africa). This sub-
study is of a cross-sectional nature and here a structured, validated lifestyle questionnaire and data 
collection forms were used to gather information regarding demographics, lifestyle, clinical and 
laboratory data (Appendix 3). We also collected blood samples to test for various biochemical 
markers, while blood pressure measurements (three readings per patient) and heart rates were also 
measured. In addition, selected anthropometric measurements were performed that included height, 
weight, BMI determination, WC, hip circumference (HC), waist-to-hip ratio (WHR), mid-upper arm 
circumference (MUAC), triceps skin fold (TSF) and biceps skin fold (BSF). Together such findings 
would allow for the evaluation of cardio-metabolic risk factors in this population.   
 
2.2 Study setting, population and sampling  
The study was conducted at Worcester CDC, located within the Worcester Hospital (Western Cape, 
South Africa). It is a public referral hospital and is also part of the metro and district health services. 
This CDC provides primary health care service and provides treatment/management of HIV-positive 
patients.   
Written informed consent was obtained from all participants (Appendix 2) by verbal 
communication (in mother tongue language) explaining the purpose and the procedures of the study. 
Here translators assisted when this was required. This study received ethical approval from the Health 
Research Ethics Committee at Stellenbosch University and also by the Department of Health 
(Western Cape Government) (refer Section 2.5 for more details).  
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2.2.1 Eligibility criteria   
All the patients in this study were enrolled at Worcester CDC and they have regular follow up.  
Recruitment was done by a part-time qualified nurse who assessed files in the clinic and then 
identified subject recruits for our study. The following is selection criteria that applied for the study 
population: 
Inclusion:  
o HIV-positive or negative patients, both male and female and registered at Worcester 
CDC 
o Age range > 20 to 55 years 
o Residents from Worcester and surrounding areas 
o Signed informed consent 
Exclusion:  
o Age < 20 and/or > 55 years 
o Not usually residing within the Cape Winelands region 
o Do not provide consent 
 
2.3 Data collection procedures 
Questionnaires were administered by the researcher and assisted by a qualified nurse. In addition, 
the researcher collected data from patient files. We determined blood pressure by using a Niscomed 
Blood Pressure Apparatus Clock Type Tabletop device (Niscomed Electro Devices Company, New 
Delhi, India). This was done in triplicate and an average value then recorded. The heart rate was 
measured by palpation method at the wrist (radial artery) and by counting the number of beats per 
one minute period. Blood samples were collected by qualified phlebotomists and immediately 
transported to the National Health Laboratory Service (NHLS) (Worcester) for analysis.  
High TC was defined as > 6.2 mmol/L, high TG as > 2.2 mmol/L and low HDL as < 1 
mmol/L, fasted blood glucose levels were measured using the photometric method. High levels of 
fasting blood glucose (FBG) defined as > 5.6 mmol/L (Appendix 4). Participants were defined as 
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diabetic if fasting glucose levels exceeded 7.0 mmol/L, if they reported a history of diabetes, or were 
currently receiving treatment for diabetes (insulin or oral hypoglycemic agents) insulin level 
determination was performed using the chemilluminescense non-competitive method. High insulin 
levels were defined as > 25 Mu/L, while IR was determined through the HOMA-IR mathematical 
calculation by using the formula: IR = Insulin mU/L× glucose mmol/L/22.5 and we defined IR as 
HOMA-IR cutoff level ≥ 2 on the basis of an approximation to the mean ± 1 SD value obtained in 
Ghanaians with normal FBG and blood pressure using the HOMA model (Amoah et al. 2003). 
Nonetheless, it should be noted that the mean HOMA-IR for normal individuals in most populations 
is between 2.1 and 2.7 (Lebovitz 2002). Specific cutoff points used for the definition of IR in some 
European and African populations range from 1.62 to 2.77 (Ascaso et al. 2003; Bonora et al. 1998; 
Ezenwaka et al. 1997; Ford and Giles 2003; Taniguchi et al. 1999). CRP levels were measured by 
the immuno turbidimetric method, high CRP was defined as > 10 mg/L (Okamura & Terada 1990). 
The Atherogenic Index of Plasma (AIP) for identifying high risk individuals for CAD was also 
calculated: AIP = log TG/HDL, low risk (AIP < 0.1), medium risk (AIP 0.1-0.24) and high risk (AIP 
> 0.24) (Dobiásová 2006). 
A complete drug history was taken for all HIV-positive individuals receiving HAART. This 
information was accessed from patient files and typically included ARV type, treatment duration and 
adherence. We also recorded CVD family history and smoking status by using a validated 
demographic questionnaire. This also provided additional information, e.g. age, home language and 
levels of education. The anthropometrical part of the study included basic measurements included: 
height and weight were measured by PD300DHR digital weight and height scale (Model 
PD300DHR, DETECTO–division of cardinal scale manufacturing company, Webb City, MO, USA). 
The height was measured to the nearest 0.1 cm with the head of the patient in the Frankfort plane 
while standing in the anatomical position with feet together on a flat surface by a calibrated 
stadiometer, and weight which were measured (with minimal clothing and without shoes) to the 
nearest 0.01 kg. BMI was calculated by dividing weight (kilograms) by height in meter squared 
(BMI; kg/m2) with specific categories (Appendix 5). Waist circumference (WC) was measured with 
a Lufkin® executive thin line tape measure (Lufkin W606PM) (Apex Tool Group, USA) at the 
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narrowest point between the lower costal border and the top of the iliac crest perpendicular to the 
long axis of the trunk (Stewart et al. 2011), while HC was determined at the greatest posterior 
protuberance of the gluteal muscles. The WHR was calculated by division of the previous two 
measurements. TSF and BSF were measured by calibrated caliper (Slim Guide Plastic Skinfold 
Caliper, brand name: CE, NexGen Ergonomics Co., Montreal, Canada), while MUAC was also 
assessed (Appendix 6). 
 
2.3.1 Interviews 
Interviews were conducted by the researcher on personal medical history and by focusing on HAART 
regimens (first or second line, naive) and a validated questionnaire was used to collect all the relevant 
information for traditional CVD risk factors (smoking, family history of CVD, HTN, DM).   
 
 2.4 Data analysis 
Data collected was captured into Microsoft Excel (Microsoft Office 2013, USA) and an explanatory 
dictionary used to describe all the variables in more detail and thereafter data were exported to 
STATA v.13 (Stata: Release 13. Statistical Software. College Station, TX: StataCorp LP, USA). For 
analysis, all continuous variables were summarized using means and standard deviation. Categorical 
data were summarized using proportion and percentages, while comparison of continuous variables 
between the three groups (first line, second line and naive) were compared using two-way analysis 
of variance (ANOVA) or Kruskal-Wallis where appropriate. The comparison of continuous variables 
between the two groups (HIV-positive on HAART and HIV-positive HAART naive) was done using 
the Mann-Whitney test. Association between two categorical variables was tested using chi-squared 
or Fisher's exact tests. P-values of ≤ 0.05 were considered statistically significant. 
 
2.5 Ethical considerations 
Great effort and patience was used to confirm that procedures in conducting the study complied with 
the ethical guidelines and principles of the international Declaration of Helsinki, South African 
Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines 
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for Research. Ethical approval for the research was sought from the Health Research Ethics 
Committee at Stellenbosch University (see Appendix 1) and also the Department of Health (Western 
Cape Government). All participants were given a consent form to read, understand and sign if they 
agreed to participate in the study. The aims of the study were also explained to all potential 
participants and that they were free to withdraw at any point, even if they previously had agreed to 
take part. The privacy and dignity of the participants were preserved and no personal identifiers 
(names or addresses) of patients were collated. Only a specific study code for each participant, their 
age and gender were recorded and subsequently used to match results obtained from laboratory 
analyses. Participants were also informed that some pain or discomfort might be felt for the collection 
of a blood sample. It was also further explained that blood was going to be drawn by a qualified and 
experienced nurse and that the samples would be used for study purposes only.  
 
2.6 Study strategy 
Figure 1 summarizes the overall study design and activities: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Diagrammatical representation of study strategy and assessments.
Ethical approval 
HIV-positive patients 
HAART naive
CDC Clinic 
HIV-positive patients on HAART
(first and second line)
1- Life style, demographic and drug history.
2- Blood pressure and heart rate measurement.
3- Collect blood samples for lab assessment. 
Anthropometric evaluation
Data analysis
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3.0 Results 
Socio-demographic characteristics of study participants 
Seventy-five subjects were recruited and included in the final analysis; the study population was 
divided into two broad categories n = 50 were HIV-positive on HAART and the other n = 25 were 
HIV-positive HAART naive. Of the 50 participants in the first group, n = 9 were males (18%) and  
n = 41 females (82%), while for the second group n = 12 were males (48%) and n = 13 females (52%) 
(P = 0.006) (Figure 1). The ages of the participants in the HIV-positive on HAART group ranged 
from 20 to 55 years with a mean of 37.1 8.8 years. For the HIV-positive HAART naive group the 
ages ranged from 20 to 50 years with a mean of 35.3 8.48 years (P = 0.4183). The duration of HIV 
diagnosis ranged from 11 to 161 months for the HIV-positive HAART and 96% were diagnosed 
more than one year ago. For those in the HIV-positive HAART naive group, the duration of HIV 
diagnosis was from 2 to124 months; 16% were diagnosed less than a year and 84% more than one 
year ago (P = 0.003). The duration of HAART ranged from 7 to 144 months for HIV-positive 
individuals on HAART with high adherence (96%). Half of HIV-positive persons on HAART had a 
positive family history of CVD while this figure rose to 60% for HIV-positive HAART naive 
individuals. In terms of lifestyle variables, 27.3% of the HIV-positive (on HAART) participants 
reported current smoking, while this figure was much higher (88%) for HIV-positive HAART naive 
individuals (Figure 2). When evaluating HIV-positive individuals on HAART in terms of WHO 
clinical stages there were 52% in stage I, 12% in stage II, 22% in stage III and 14% in stage IV. For 
the HAART naive group the overwhelming majority (96% and 4%) were in stage I and II 
respectively, no participants were recorded in stage III and IV for HIV-positive HAART naive (Table 
1). 
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Table 1: Socio-demographic characteristics of study participants. 
Variables HIV+ HAART naive HIV+ on HAART P-value 
Age (years) 
P = 0.4183 Mean  35.36  37.1    
SD 8.48     8.85 
Gender, n (%) 
P = 0.006 Female 13 (52%) 41(82%) 
Male 12 (48%) 9 (18%) 
Smoking status, n (%) 
P = 0.0001 Yes 22 (88%) 19 (27.3%) 
No 3 (12%) 31 (22.7%) 
HIV time (months) 
P = 0.003 Median 35 72 
IQR 62 56 
HAART duration (months) 
- Median - 60 
IQR - 51 
WHO clinical stages, n (%) 
- 
I 24 (96%) 26 (52%) 
II 1 (4%) 6 (12%) 
III 0 (0%) 11 (22%) 
IV 0 (0%) 7 (14%) 
 
Abbreviations: HIV+: HIV-positive, SD: Standard deviation, IQR: Interquartile range.  
P-values of ≤ 0.05 were considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Gender proportion of HIV-positive HAART naive and HIV-positive (on HAART). Significant 
difference in gender: HIV-positive HAART naive versus HIV-positive on HAART (*P = 0.006).  
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Figure 2: Smoking proportion of HIV-positive HAART naive and HIV-positive (on HAART). Significant 
difference in smoking proportion: HIV-positive HAART naive versus HIV-positive on HAART (*P = 0.0001). 
 
 
All the subjects on HAART treatment were further divided into two sub-groupings i.e. first line (n = 
25) and second line treatment (n = 25). These sub-groups were subsequently analyzed and here 
participants on first line treatment used a combination of HAART drugs with NRTIs and NNRTI 
provided as FDC: EFV+FTC+TDF (68%), TDF+3TC+EFV (16%), AZT+3TC+NVP (16%). 
Subjects on second line treatment used a combination of a boosted PI plus two NRTIs drugs: 
LPV/r+AZT+3TC (56%), LPV/r+3TC+TDF (44%) (Figure 3).  
 
 
 
Figure 3: Percent distribution of types of HAART regimens in first versus second line. EVF- Efavirenz, FTC- 
Emtricitabine, TDF- Tenofovir, 3TC- Lamivudine, AZT- Zidovudine, NVP- Nevirapine, LPV/r- 
Lopinavir/ritonavir. 
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The socio-demographic characteristics of HIV-positive individuals on first and second line treatment 
is presented in Table 2, where 28% were males and the majority females for first line treatment. For 
second line treatment this was skewed even more towards females, i.e. 8% males versus 92% 
females. For the HIV-positive HAART naive group the pattern was different and here 48% were 
males and 52% females (P = 0.007) (Figure 4). Ages for first line treatment ranged from 20 to 53 
years with a mean of 36.24  8.65 years, while for the second line ages it ranged from 26 to 55 years 
with a mean of 37.96  9.14 years. For the HIV-positive HAART naive group the ages ranged from 
20 to 50 years with a mean of 35.36  8.48 years (P = 0.931). For the HIV-positive group the duration 
of HIV diagnosis ranged from 11 to 147 months for first line and 34 to 161 months for second line 
treatment, for the HAART naive group it ranged between 2 to 124 months.  
 
Table 2: Socio-demographic characteristics of first and second line treatments.  
Variables HIV+ HAART naive First line Second line P-value 
Age (years) 
P = 0.931 Mean 35.36 36.24 37.96 
SD 8.48 8.65 9.14 
Gender, n (%) 
P = 0.007 Female 13 (52%) 18 (72%) 23(92%) 
Male 12 (48%) 7 (28%) 2 (8%) 
Smoking status, n (%) 
P = 0.0001 Yes 22 (88%) 13 (52%) 6 (24%) 
No 3 (12%) 12 (48%) 19 (76%) 
HIV time (months) 
P = 0.0008 Median 35 63 81 
IQR 62 68.5 71 
HAART duration (months) 
P = 0.0182 Median - 48 65 
IQR  54 47 
Adherence on HAART, n (%) - 25 (100%) 23 (92%) P = 0.149 
WHO clinical Stages, n (%) 
- 
I 24 (96%) 16 (64%) 10 (40%) 
II 1 (4%) 1 (4%) 5 (20%) 
III 0 (0%) 4 (16%) 7 (28%) 
IV 0 (0%) 4 (16%) 3 (12%) 
P-values of ≤ 0.05 were considered statistically significant. 
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The corresponding duration of HAART for first line and second line treatment ranged from 7-120 
months and 25-144 months, respectively (P = 0.0182), with complete adherence for the first line (n 
= 25; 100%) and also relatively high for the second line (92%). A strong proportion of the naive 
group reported as current smokers (n = 22; 88%), with 52% and 24% for first and second line, 
respectively (P = 0.0001) (Figure 5). WHO clinical stages for the first line were: 64% in stage I, 4% 
in stage II and 16% for both stages III and IV, respectively. For second line treatment the data 
revealed: 40%, 20%, 28% and 12% in stages I, II, III and IV, respectively, compared to 96% in stage 
I and 4% in stage II for HIV-positive HAART naive.  
 
 
 
 
 
 
 
Figure 4: Gender proportion between HIV-positive HAART naive, first line and second line treatment. 
Significant difference in gender proportion between HIV-positive HAART naive, first line and second line 
persons (*P = 0.007). 
 
 
 
 
 
 
 
Figure 5: Smoking proportion between HIV-positive HAART naive, first line and second line treatment. 
Significant difference in smoking proportion between HIV-positive HAART naive against first line and second 
line persons (*P = 0.0001).  
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The characteristics of the study population are summarized in Table 3. For the HIV-positive group 
on HAART the following data emerged for BMI categories: 16% underweight, 36% healthy weight, 
22% in class 1 obesity, 22% in class 2 and 4% in class 3 obesity (Appendix 5). For the HIV-positive 
HAART naive group 28% were underweight, 56% displayed healthy weight, 12% class 1 and 4% 
class 2 obesity (Figure 6). According to IDF ethnic-specific values for WC (Appendix 6), 58% 
females of the HIV-positive (on HAART) displayed WC  80 cm while only 2% males exhibited a 
WC  94 cm. This was significantly higher than that of the HIV-positive HAART naive where 8% 
females and 4% males displayed WC values above the stipulated thresholds (P = 0.0001). The median 
(IQR) for TSF in HIV-positive on HAART were higher than for the HIV-positive HAART naive 
group (P = 0.0038) (Figure 7). Moreover, the median (IQR) for BSF in the HIV-positive (on 
HAART) group was also higher than the HIV-positive HAART naive group (P = 0.0004) (Figure 8). 
A similar pattern was found for the MUAC data (P = 0.0417) (Figure 9). In addition, height, body 
weight and HC for the HIV-positive (on HAART) group were significantly different compared to 
the HIV-positive HAART naive group (P = 0.03, P = 0.04 and P = 0.0171, respectively) (Table 3). 
 
                                         
 
 
                                                    (a)                                                        (b) 
 
                      Figure 6: Proportion of BMI in (a) HIV-positive HAART naive and (b) HIV-positive on HAART. 
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Figure 7: TSF analysis for HIV-positive HAART naive and HIV-positive on HAART. Significant difference 
in TSF between HIV-positive HAART naive versus HIV-positive on HAART (*P = 0.0038). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: BSF analysis for HIV-positive HAART naive and HIV-positive on HAART. Significant difference 
in BSF between HIV-positive HAART naive against HIV-positive on HAART (*P = 0.0004). 
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Figure 9: MUAC analysis for HIV-positive HAART naive and HIV-positive on HAART. Significant 
difference in MUAC between HIV-positive HAART against HIV-positive on HAART (*P = 0.0417). 
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Table 3: Anthropometric characteristics of HIV-positive individuals (on HAART) and HIV-positive HAART 
naive. 
Variables 
HIV+ HAART 
naive 
HIV+ on 
HAART 
P-value 
Height (cm) mean SD 162.08 8.21 157.43 9.03 P = 0.03 
Weight (kg) mean SD 54.77 10.5 62.96 18.4 P = 0.04 
BMI categories (Appendix 5) 
P = 0.09 
Underweight, < 18.5Kg/m2, n (%) 7 (28%) 8 (16%)  
Healthy weight, 18.5–24.9 Kg/ m2, n (%) 14 (56%) 18 (36%) 
Class 1 obesity, overweight, 25–29.9 Kg/m2, n (%) 3 (12%) 11 (22%) 
Class 2 obesity, obesity, 30–39.9 Kg/m2, n (%)   1 (4%) 11 (22%) 
Class 3 obesity, morbid obesity, > 40 Kg/m2, n (%) 0 (0%) 2 (4%) 
WC (Appendix 6) 
P = 0.0001 Men  94 cm 1 (4%) 1 (2%) 
Women  80 cm 2 (8%) 29 (58%) 
HC 
P = 0.0171 
Mean SD 92.02 8.55 99.84 14.82 
WHR, n (%) (Appendix 6) 
P = 0.109 
Excellent  
Male < 0.85 6 (24%) 2 (4%) 
Female < 0.75 1(4%) 2 (4%) 
Good 
Male 0.85-0.89 3 (12%) 3 (6%) 
Female  0.75–0.79 4 (16%) 7 (14%) 
Average  
Male 0.90–0.95  3 (12%) 3 (6%) 
Female  0.80–0.86  4 (16%) 14 (28%) 
At Risk 
Male > 0.95 0 (0%) 1 (2%) 
Female > 0.86 4 (16%) 18 (36%) 
TSF (mm) 
P = 0.0038 Median 10 15 
IQR 5 11 
BSF (mm) 
P = 0.0004 Median 4 8 
IQR 3 7 
MUAC (cm) 
P = 0.0417 Median 24.5 27.15 
IQR 2 7.3 
Abbreviations: BMI: Body mass index, WC: Waist circumference, HC: Hip circumference, WHR: Waist-to-hip ratio, TSF: 
Triceps skin fold, BSF: Biceps skin fold, MUAC: Mid-upper arm circumference.  
- P-values of ≤ 0.05 were considered statistically significant. 
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The characteristics of HIV-positive individuals on first and second line treatment compared to HIV-
positive HAART naive are presented in Table 4. For BMI categories for the first line group there is 
12% underweight, 40% healthy weight, 20% class 1 obesity and 28% class 2 obesity. For the second 
line 20% were underweight, 32% healthy weight, 24% class 1 obesity, 16% class 2 obesity and 8% 
class 3 obesity. For the HIV-positive HAART naive group 28% were underweight, 56% healthy 
weight, 12% class 1 obesity and 4% class 2 obesity (P = 0.117) (Appendix 5). Several of the 
anthropometric parameters (WC, WHR, TSF, BSF and MUAC) showed changes with first and 
second line treatment compared to HIV-positive HAART naive (Figure 10, 11 and 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: TSF analysis for HIV-positive HAART naive, first line and second line treatment. Significant 
difference for TSF between HIV-positive HAART naive versus first line (*P = 0.0222) and second line (*P = 
0.0067) groups. There was no significant difference between first line and second line treatments (P = 0.3410). 
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Figure 11: BSF analysis for HIV-positive HAART naive, first line and second line treatment. Significant 
difference for BSF between HIV-positive HAART naive versus first line (*P = 0.001) and second line              
(*P = 0.0042) groups. There was no significant difference between first line and second line treatments               
(P = 0.6404). 
 
 
 
 
 
 
 
 
 
Figure 12: MUAC analysis for HIV-positive HAART naive, first line and second line treatment. Significant 
difference for MUAC between HIV-positive HAART naive versus first line persons (*P = 0.0077). There were 
no significant difference between HIV-positive HAART naive and second line treatment (P = 0.1588) and 
between first line and second line treatments (P = 0.5408).  
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Table 4: Anthropometric characteristics for first and second line treatment groups versus the HIV-positive 
HAART naive group. 
Variables HIV+ HAART naive First line Second line P-value 
Height (cm) mean SD 162.08 8.21  158.03 9.59 156.82 8.58 P = 0.735 
Weight  (kg) mean SD 54.77 10.5 61.78 14.1 64.14 22.1 P = 0.001 
BMI categories (Appendix 5) 
P = 0.117 
Underweight  18.5Kg/m2, n (%) 7 (28%) 3 (12%) 5 (20%) 
Healthy weight 18.5–24.9 Kg/ m2, n (%)  14 (56%) 10 (40%) 8 (32%) 
Class 1 obesity, overweight 25–29.9 
Kg/m2, n (%) 
3 (12%) 5 (20%) 6 (24%) 
Class 2 obesity, obesity 30–39.9 
Kg/m2, n (%)   
1 (4%) 7 (28%)  4 (16%) 
Class 3 obesity, morbid obesity  40 
Kg/m2, n (%) 
0 (0%)  0 (0%)  2 (8%) 
WC (Appendix 6) 
P = 0.0001 Men  94 cm 1 (4%) 1 (4%) 0 (0%) 
Women  80 cm 2 (8%) 13 (52%) 16 (64%) 
HC 
P = 0.008 
Mean SD 92.02 8.55 97.93 12.87 101.76 16.57 
WHR, n (%) (Appendix 6) 
P = 0.268 
Excellent 
Male  0.85 6 (24%) 2 (8%) 0 (0%) 
Female  0.75 1 (4%) 1 (4%) 1 (4%) 
Good 
Male (0.85–0.89)  3 (12%) 1 (4%) 2 (8%) 
Female (0.75–0.79) 4 (16%) 3 (12%) 4 (16%) 
Average  
Male (0.90–0.95)   3 (12%) 3 (12%) 0 (0%) 
Female (0.80–0.86)  4 (16%) 5 (20%) 9 (36%) 
At Risk 
Male  0.95 0 (0%) 1 (4%) 0 (0%) 
Female  0.86 4 (16%) 9 (36%) 9 (36%) 
TSF (mm) 
P = 0.0114 Median 10 14 18 
IQR 5 10 13 
BSF (mm) 
P = 0.0017 Median 4 8 8 
IQR 3 6 6 
MUAC (cm) 
P = 0.044 Median 24.5 27 27.3 
IQR 2 7.5 9 
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There were no significant differences between groups for blood metabolites tested in this study 
(Appendix 4) except for low HDL in the HIV-positive HAART naive group (Figure 13) (Table 5). 
Figure 14 represents the proportional analysis of IR for the HIV-positive (on HAART) group (n = 
18; 36%) versus HIV-positive HAART naive persons (n = 8; 32%). The median (IQR) values of 
blood metabolites for HIV-positive on HAART versus HIV-positive HAART naive are summarized 
in Appendix 7. 
  
Table 5: Blood metabolite analysis for HIV-positive (on HAART) individuals versus HIV-positive HAART 
naïve (Appendix 4). 
Variables HIV+ HAART naive HIV+ on HAART P-value 
TC, n (%) 
P = 0.362 
Desirable 21 (84%)  44 (88%) 
Borderline 3 (12%) 6 (12%) 
High 1 (4%) 0 (0%) 
LDL, n (%) 
P = 0.066 
Desirable 16 (64%) 26 (52%) 
Borderline 4 (16%) 20 (40%) 
High 5 (20%) 4 (8%) 
HDL, n (%) 
P = 0.022 Desirable 8 (32%) 30 (60%) 
Low 17 (68%) 20 (40%) 
TG, n (%) 
P = 0.429 Desirable 23 (92%) 45 (90%) 
High 2 (8%) 5 (10%) 
CRP, n (%) 
P = 0.842 Normal 20 (80%) 39 (78%) 
High 5 (20%) 11 (22%) 
FBG, n (%) 
P = 0.145 Normal 21 (84%) 37 (74%) 
High 4 (16%) 13 (26%) 
Insulin, n (%) 
P = 0.320 
Normal 21 (84%) 37 (74%) 
Low 3 (12%) 5 (10%) 
High 1 (4%) 8 (16%) 
IR HOMA index, n (%) 
P = 0.687 Normal 17 (68%) 32 (64%) 
resistant 8 (32%) 18 (36%) 
AIP, n (%) 
P = 0.620 
Low risk (AIP:  0.1) 21 (84%) 37 (74%) 
Medium risk (AIP: 0.1–0.24) 1 (4%) 3 (6%) 
High risk (AIP:  0.24) 3 (12%) 10 (20%) 
 
Stellenbosch University  https://scholar.sun.ac.za
 70 
 
There was strong significant difference in LDL percentages between HIV-positive persons on first 
and second line treatments and HIV-positive HAART naive persons (P = 0.006) (Table 6). However, 
we found no statistically significant differences for any of the other parameters here assessed 
(Appendix 4). For the first line group there was 36% with low HDL and 44% for the second line 
group, versus 68% for the HIV-positive HAART naive group (P = 0.065) (Figure 13). As before, 
proportional analysis showed the IR in the first line group (32%) and 44% with second line treatment 
(P = 0.510) (Figure 14). The proportional analysis also showed both first line and second line groups 
at higher risk for CVD; 20% for both first and second line groups (as per AIP categories) compared 
to the HIV-positive HAART naive group (12%) (Figure 16). The proportion of SBP and DBP for 
HIV-positive HAART naive versus HIV-positive (on HAART) groups is indicated in Figure 17. The 
median (IQR) values of blood metabolites for HIV-positive persons on first and second line 
treatments versus HIV-positive HAART naive persons are summarized in Appendix 8. 
 
 
 
                             HDL in HIV-positive HAART naive                     HDL in HIV-positive on HAART  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Distribution patterns of HDL (%). (a) HIV-positive HAART naive versus HIV-positive (on 
HAART), significant difference found (P = 0.022); (b) HDL distribution patterns between first line and second 
line treatments.  
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Table 6: Blood metabolite analysis for HIV-positive persons on first and second line treatments versus HIV-
positive HAART naive persons (Appendix 4). 
Variables HIV+ HAART naive First line Second line P-value 
TC, n (%)  
P = 0.594 
Desirable 21 (84%) 23 (92%) 21 (84%) 
Borderline 3 (12%) 2 (8%) 4 (16%) 
High 1 (4%) 0 (0%) 0 (0%) 
LDL, n (%) 
P = 0.006 
Desirable 16 (64%) 9 (36%) 17 (68%) 
Borderline 4 (16%) 15 (60%) 5 (20%) 
High 5 (20%) 1 (4%) 3 (12%) 
HDL, n (%) 
P = 0.062 Desirable 8 (32%) 16 (64%) 14 (56%) 
Low 17 (68%) 9 (36%) 11 (44%) 
TG, n (%) 
P = 0.661 Desirable 23 (92%) 23 (92%) 22 (88%) 
High 2 (8%) 2 (8%) 3 (12%) 
CRP, n (%) 
P = 0.573 Normal 20 (80%) 18 (72%) 21 (84%) 
High 5 (20%) 7 (28%) 4 (16%) 
FBG, n (%) 
P = 0.350 Normal 21 (84%) 18 (72%) 19 (76%) 
High 4 (16%) 7 (28%) 6 (24%) 
Insulin, n (%) 
 
P = 0.646 
Normal 21 (84%) 18 (72%) 19 (76%) 
Low 3 (12%) 3 (12%) 2 (8%) 
High 1 (4%) 4 (16%) 4 (16%) 
IR HOMA index 
P = 0.510 Normal 17 (68%) 17 (68%) 14 (56%) 
resistant 8 (32%) 8 (32 %) 11 (44%) 
AIP, n (%) 
P = 0.3542 
Low risk (AIP:  0.1) 21 (84%) 19 (76%) 18 (72%) 
Medium risk (AIP: 0.1–0.24) 1 (4%) 1 (4%) 2 (8%) 
High risk (AIP:  0.24) 3 (12%) 5 (20%) 5 (20%) 
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                           IR in HIV-positive HAART naive                         IR in HIV-positive on HAART 
 
 
 
 
 
 
 
 
                                                                                  
 
 
 
 
 
 
 
 
Figure 14: Distribution patterns of IR (%). (a) HIV-positive HAART naive versus HIV-positive (on HAART); 
and (b) IR distribution patterns between first line and second line treatments.  
 
 
 
                                          
 
 
 
 
 
 
 
 
 
 
 
 
                                                      (a)                                                                          (b) 
 
 
Figure 15: Proportion of AIP in (a) HIV-positive HAART naive and (b) HIV-positive (on HAART) groups. 
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Figure 16: Proportion of AIP for first line and second line treatments versus HIV-positive HAART naive 
individuals (P = 0.3542). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Proportion of SBP and DBP for HIV-positive HAART naive versus HIV-positive (on HAART) 
groups. 
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4.0 Discussion 
Although HAART has significantly improved the survival of HIV-infected patients, there are increased 
concerns regarding the onset of co-morbidities (e.g. cardio-metabolic complications) and mortalities in 
such individuals (Lohse et al. 2007; Sackoff et al. 2006). Although South Africa is burdened with the 
highest number of HIV-infected individuals globally, there is a relative paucity of data regarding 
potential links between HIV infection, HAART and cardio-metabolic risk/onset. This cross-sectional 
study therefore investigated the prevalence of cardio-metabolic risk factors in HIV-infected individuals 
on HAART within the Cape Winelands region of South Africa. Here we collected anthropometric, 
biochemical and lifestyle-related data for HIV-positive HAART naive (n =25) and HIV-positive 
individuals on HAART (n = 50) patients (20 – 55 years old) at the Worcester CDC (Worcester, Western 
Cape, South Africa) during 2014 and 2015. Subjects on HAART were further divided into two sub-
groupings, i.e. first line (n = 25) and second line treatments (n = 25). The main findings of this study 
are: a) the relatively high prevalence of traditional, cardio-metabolic lifestyle risk factors in HIV-
infected individuals; b) a large proportion of HIV-positive HAART naive patients can be categorized 
into groups with relatively low HDL and high LDL levels, respectively; and c) HAART enhanced 
anthropometric measures of obesity.   
 
Relatively high prevalence of traditional lifestyle risk factors 
Relatively high prevalence of traditional lifestyle risk factors 
Our data reveal a relatively high prevalence of smoking, i.e. 88% for the HIV-positive HAART naive 
group and 27.3% for the HIV-positive group on HAART. However, as we did not include a HIV-
negative control group these data are difficult to interpret but our findings are in agreement with 
previous studies that established that HIV-infected persons displayed higher prevalence of smoking 
(Lifson & Lando 2012; Reynolds 2009).  Additional studies with an HIV-negative control are required 
to assess whether this indeed the case for the Worcester population. There are relatively limited data 
regarding cigarette smoking prevalence among HIV-positive people in the Western Cape and in South 
Africa, making meaningful comparisons difficult. It also remains unclear why smoking prevalence is 
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so high in HIV-infected individuals in the Cape Winelands region and we speculate that this may be a 
combination of factors that likely include poor socio-economic backgrounds, a limited understanding 
of the damaging effects of smoking, and as a coping mechanism to deal with the stress when diagnosed 
as HIV-positive. Further studies are required to investigate this concerning phenomenon in HIV-
positive individuals (versus negative controls) in the Cape Winelands region and the rest of South 
Africa.   
We did not find any significant changes for HTN prevalence in HIV-infected individuals 
included in this study. Previous studies found a range of findings for HTN in HIV-positive patients with 
some reporting increased risk with ART (Gazzaruso et al. 2003) while others found no association 
(Bergersen et al. 2003; Jerico et al. 2005). Such differences may be influenced by a number of factors 
that can include differences in sample sizes, distinct presentation of lifestyle risk factors and methods 
employed to determine HTN in patients. Of note, the lifestyle questionnaire data established that more 
than half of the HIV-positive individuals indicated a prior family CVD history. The reasons for this 
phenomenon are unclear but it is likely that same arguments earlier put forward (for high smoking 
prevalence) may also apply in this instance. However, without an HIV-negative control group we cannot 
make any definitive conclusions in this instance. Compounding this picture is that the majority of cohort 
here studied (92%) falls into a relatively young age group (~45 years for men; ~55 years for women) 
and may potentially constitute a risk factor as such individuals will usually display an even higher risk 
as they continue to age (DAD Study Group 2003). This is in agreement with others that found that 
younger, HIV-infected persons are at greater risk of developing CVD than their peers of similar age 
(Carter 2010; Currier et al. 2008).  
 
Relatively high proportion of HIV-positive HAART naive patients categorized into groups with 
relatively low HDL and high LDL levels, respectively 
The lipid blood metabolite analyses (TC, LDL, HDL and TG) did not reveal significant changes when 
comparing HIV-positive on HAART versus HIV-positive HAART naive groups. Likewise, when such 
values were compared to established cut-off thresholds (NCEP Expert Panel 2001) there were no 
significant changes. However, in this case HDL levels in the HIV-positive HAART naive group were 
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lower than the HAART group although this did not reach statistical significance (P = 0.06). This 
suggests that untreated HIV-infected persons may potentially be at increased risk for CVD onset before 
treatment initiation and it is likely that such effects are mediated by the virus itself and/or lifestyle-
related risk factors such as smoking. These findings are in agreement with others that found that 
untreated HIV individuals are at greater risk due to virus-induced effects such as chronic inflammation 
that may contribute to the onset of atherosclerosis (Riddler et al. 2003; Triant et al. 2007). This notion 
was echoed by additional analyses performed on our data set. When HDL and LDL data were placed 
into various, established sub-groups (NCEP Expert Panel 2001) then 68% of the naive individuals could 
be categorized as “low HDL”. However, with HAART this situation improved with this number 
declining to 40% (P = 0.022). Of note, first line treatments decreased the low HDL numbers to 36% 
compared to 44% with second line treatment. This demonstrates that patients on second line treatment 
display an improved HDL profile compared to the naive group, although this decrease is not as robust 
as for the first line therapy. Such findings are in agreement with previous studies performed in the 
United States and other parts of sub-Saharan Africa that established that treatment-naive HIV-infected 
patients exhibit significantly lower levels HDL (Nguemaïm et al. 2010; Obirikorang et al. 2010; Shor-
Posner et al. 1993).  
Data from our study did not reveal any significant differences for CRP levels between the HIV-
positive HAART naive and HIV-positive on HAART and likewise for comparisons between first and 
second line treatments. This indicates lack of an inflammatory response in HIV-infected persons within 
the Cape Winelands region. In support others reported the absence of opportunistic infections in HIV-
positive individuals (Lawn et al. 2001), while Wilson et al. (2011) established normal CRP levels in a 
South African cohort (Wilson et al. 2011).  
There were no significant difference when comparing FBG and insulin levels between HIV-
positive HAART naive and HIV-positive on HAART. This also applied when additional tests were 
completed for first and second line treatments. Our findings are consistent with others (Muthumani et 
al. 2003) who found no significant changes in FBG levels in HIV-positive subjects compared to 
controls, while Hadigan et al. (2001) established that FBG levels remain within the normal range in 
most patients receiving potent ARV. Other studies reported the association of PI usage with impaired 
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FBG and DM (Carr & Cooper 2000; Palella et al. 1998), while Gadd (2006) found that high glucose 
levels are associated with low CD4 count in HIV-positive individuals. For our study we speculate that 
normal FBG levels may manifest due to the following possibilities: a) from the literature it is well 
documented that impaired glucose metabolism and IR are linked to defects in lipid metabolism (Magkos 
& Mantzoros 2011) while our study did not reveal dyslipidemia; b) the relatively small sample size;            
c) OGTT is a more sensitive test to detect glucose abnormalities in HIV-infected patients who display 
normal FBG levels (Gianotti et al. 2011); and d) lack of CD4 counts to assess disease progression.   
We performed additional analyses to gain greater insights into our findings and calculated 
HOMA-IR values for the different groups investigated in this study. However, there were no significant 
changes/patterns between the naive and HAART groups indicating that IR is not a major factor in this 
population. By contrast, other South African studies (Kiage et al. 2013; Menezes et al. 2014) found that 
short-term ART (90 days treatment) was associated with a propensity towards IR development 
regardless of the ART employed. In support, some reported a higher risk for IR in ART patients versus 
naive HIV-infected patients (Idiculla et al. 2011). How do we explain our results in this regard?  We 
are of the opinion that such differences may be due to the relatively small sample size of this study, the 
lack of a control group (HIV-uninfected subjects) to define more precise HOMA-IR cut-off points, and 
lack of CD4 count and viral load that are strongly associated with IR onset. For example, Squillace et 
al. (2009) found a significant association between a high CD4 count and IR, while El-Sadr et al. (2005) 
demonstrated an inverse relationship between CD4 count and IR. AIP is a simple and practical ratio for 
evaluation of CVD risk and may offer greater diagnostic utility than sole use of lipid profiles, especially 
for HIV-positive patients (Lemieux et al. 2001). Moreover, it correlates more closely with small LDL 
and HDL particles which are highly atherogenic (Dobiásová & Frohlich 2001). In light of this, we 
performed AIP analysis but this did not yield any significant differences. Thus the early data suggest 
that HIV-positive individuals in the Cape Winelands region are not at increased risk of atherogenesis.  
However, sample size number should be increased to confirm this and additional tests should be 
considered to improve quality of findings generated, e.g. employment of the high-sensitivity CRP test.  
In addition, functional assessments such as carotid IMT may further strengthen the conclusions derived, 
although costs and logistics are a serious consideration.    
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HAART improved anthropometric measures of obesity  
The anthropometric data demonstrated significant improvements in weight gain with HAART and this 
applied equally for first and second line treatments employed. This is in agreement with others that 
found increased weight and improved survival with HAART (May et al. 2006). Our findings show 
significant differences for TSF, BSF, WC and MUAC between the naive and HAART groups and this 
applied for first and second line treatments. These data therefore indicate that with HAART there is 
improved well-being of patients and a general restoration to health (George et al. 2009). 
Of concern, however, is that the HAART individuals displayed higher levels of obesity when 
assessed by established cut-off values. As there is a relatively large discrepancy in terms of recruitment 
numbers (males versus females) between the naive and HAART groups, this is a factor that should be 
taken into consideration. The higher female numbers in the HAART group may therefore help explain 
increased manifestation of obesity in this group. In agreement, Nell et al. (2015) showed that females 
on prolonged HAART also displayed increased prevalence of obesity. The reasons for this are unclear 
but it may relate to cultural or lifestyle choices (Hurley et al. 2011), e.g. factors such as poor nutritional 
intake and lack of exercise may be implicated. However, additional studies are required to pursue this 
interesting notion. According to WHO (2011) cut-off points and risk of metabolic complications, the 
higher levels of obesity (e.g. WHR ≥ 0.86 in HIV-positive [on HAART]) (Appendix 6) puts such 
individuals at risk for the onset of future cardio-metabolic complications (Rasheed et al. 2008; WHO 
2011).  
 
Limitations 
The lack of an HIV uninfected control group limits our ability to attribute the changes observed to 
HAART, while the sample size was also relatively small with a strong gender bias for the HIV-positive 
(on HAART) group. This is generally due to males being the sole breadwinner and hence unable to take 
time off from work for medical care and/or contribute to research projects. This observation is in 
agreement with previous research work published by our group (Nell et al. 2015). In addition, we were 
unable to include CD4 count and viral load results in our study as there was a delay with processing of 
samples.  Finally, we included various race groups – Coloureds and Blacks – in our research study and 
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this may have also impacted on our findings and conclusions. Future studies should recruit additional 
numbers and then sub-divide the groups into specific race groupings – this should enhance the quality 
of conclusions reached. 
 
4.1 Conclusion 
The study established the prevalence of several traditional CVD risk factors (smoking, family history, 
age) in both HIV-positive naive and HIV-positive on HAART in the Cape Winelands region of South 
Africa. HAART improved several measure of weight gain and the lipid profile, suggesting a restoration 
to health and well-being. However, there was a relatively high prevalence of obesity in the HIV-positive 
(on HAART) group and especially for females thus placing them at greater risk for future cardio-
metabolic complications onset. We are unable to distinguish whether this risk is due to HAART or 
lifestyle-related risk factors and this question requires further investigations.  In light of these findings 
we recommend that clinicians should be mindful of lifestyle-related CVD risk factors in HIV-positive 
individuals and make an effort to counsel patients to adopt improved lifestyle choices such as improved 
nutritional intake, smoking cessation and increased exercise. This can be monitored on a regular basis 
in follow-up sessions. Moreover, lipid profile (HDL, LDL) assessment may be useful to employ in the 
clinic to evaluate HIV-positive individuals (especially upon admission) and to be aware that such 
patients may be at a higher risk of cardiac complications.  
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Appendix 2  
Participant information leaflet and consent form 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM 
 
 
TITLE OF THE RESEARCH PROJECT: 
WINELANDS HAART to HEART STUDY 
 
REFERENCE NUMBER: N12/12/086 
 
PRINCIPAL INVESTIGATOR: Prof MF Essop 
 
ADDRESS: 
Department of Physiological Sciences 
Mike de Vries Building 
Room 2005a  
Stellenbosch University 
 
CONTACT NUMBER: 021 8083146 
 
You are being invited to take part in a research project. Please take some time to 
read the information presented here, which will explain the details of this project.  
Please ask the study staff or doctor any questions about any part of this project that 
you do not fully understand.  It is very important that you are fully satisfied that you 
clearly understand what this research entails and how you could be involved. Also, 
your participation is entirely voluntary and you are free to decline to participate. If 
you say no, this will not affect you negatively in any way whatsoever. You are also 
free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines 
for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
 
 
What is this research study all about? 
 This study will only be done in the Stellenbosch district and surrounding 
areas.  We will need approximately 300 Patients. We are trying to gather 
information on laboratory tests, body composition and patient questionnaires 
profiles of chronic HIV patients on ARV treatment (1st and 2nd line).  By getting 
this information we would be able to assess the attenuation of metabolic 
function and contractail dysfunction caused by ARV treatment.  
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 As Africa adopts a more westernised lifestyle there is a higher incidence of 
HIV infection, diabetes and heart diseases.   
Your blood will be taken by a registered medical nurse.  It will then be sent away to 
Pathcare (Stellenbosch) where metabolic-associated parameters will be measured.  
Other biochemical tests that will be done by Pathcare include C-reactive protein 
measurements. The remainder of your blood samples will be used to obtain genetic 
material (RNA). 
The blood presser assessment, evaluation of cardiac function (ECG, 
echocardiography and carotid intima media thickness), full anthropometric 
evaluation and life style questionnaire will be done at the clinic 
Why have you been invited to participate? 
 We are trying to gather information on laboratory tests, body composition and 
patient questionnaires profiles of chronic HIV patients on ARV treatment (1st 
and 2nd line). By donating blood to our study you will be helping us to 
determine these profiles and how we can relate them to the current 
diagnostic tests to investigate cardio-metabolic effects of ARV treatment.  By 
getting this information we would be able to assess the attenuation of 
metabolic function and contractail dysfunction caused by ARV treatment. 
With your help we hope to identify the suitable therapeutic interventions that 
will blunt metabolic dysfunction, oxidative stress and enhance mitochondrial 
function under conditions where PIs are chronically administered. 
 
What will your responsibilities be? 
 As we need to examine the selected patients and then take the blood for 
laboratory tests and lifestyle questionnaire regarding your line of ARV 
treatment. A registered anthropometrist, Dr Theo Nel, will also perform 
anthropometric measurements that include waist circumference, waist: hip 
ratio, height and mass. 
 
Will you benefit from taking part in this research? 
 Although there may not be any direct benefits to me/the participant by 
participating at this stage, future generations may benefit if the researchers 
succeed in finding out more about how ARV treatment can lead to metabolic 
dysfunction and cardiac disease.  If you choose to know the results of your 
blood tests we will make these available. However, you would have to 
discuss this information with your personal doctor, at your own cost, in order 
to assess your medical status with ARV treatment (metabolic and cardiac 
status).   
 
Are there in risks involved in your taking part in this research? 
There are no more than minimal medical or physiological risks associated with this 
study. 
 
 I/the participant may feel some pain associated with having blood drawn from 
a vein and may experience some discomfort, bruising and/or slight bleeding 
at the site. 
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If you do not agree to take part, what alternatives do you have? 
 It is your decision to participate or not and nothing will be done from the 
researchers’ part to in any way to persuade you to take part.   
 
Who will have access to your medical records? 
 Only the principal researcher (Prof Faadiel Essop and the following masters 
student: Dr. Faten Abaid) will have access to your data and records. All 
information will be treated with respect and utmost confidentiality.  Under no 
circumstances will your name or any form of identification be used in any 
publication, poster, lecture or thesis that results from this study.  Professor 
Faadiel Essop and Dr. Faten Abaid will be the only authorised personnel who 
will have access to your results from this study as well as the lifestyle 
questionnaire and anthropometric measurements. 
 
What will happen in the unlikely event of some form injury occurring as a 
direct result of your taking part in this research study? 
 Not applicable here. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
 No, you will not be paid to take part in the study.  There will be no costs 
involved for you, if you do take part.  Travelling costs in order to get to the 
Department of Physiological Sciences will not be covered by this study and 
you will need to cover this cost yourself. 
 
Would you like to know the results of your blood tests? 
 Please indicate by marking the correct box with an X 
          YES 
                    NO 
 
Is there anything else that you should know or do? 
 You can contact Professor MF Essop on 021 808 3146 if you have any further 
queries or encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if 
you have any concerns or complaints that have not been adequately 
addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own 
records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (Investigation of cardio-metabolic effects of ARV 
treatment in the winelands region). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not 
been pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor 
or researcher feels it is in my best interests, or if I do not follow the study 
plan, as agreed to. 
 
 
Signed at (place) ......................…………….. on (date) …………....………... 
 
 ..............................................................   .................................................... 
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use a interpreter.  (If a interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at (place) ..............…........…………….. on (date) …………....………... 
 
 
 ..............................................................   .................................................... 
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..………….. using the language medium of Tswana/English. 
 We encouraged him/her to ask questions and took adequate time to 
answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question 
satisfactorily answered. 
 
 
Signed at (place) ......................…......……….. on (date) ……….……………….. 
 
 
 
 ..............................................................   .................................................... 
Signature of interpreter Signature of witnes
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Appendix 3 
DATA SHEET 
________________________________________________________________ 
Project title: Cape Winelands HAART 2 HEART 
Ethics approval nr: N12/12/086  
                                                    IDENTIFICATION CODE: CWH2H________    
Date of interview:  
Interviewer:  
Health District Site: 
 
Worcester TC Newman Mbekweni Stellenbosch 
Age:  
Blood pressure (Sys/Dia):  
Heart rate (beats/min):  
HIV classification 
 
Negative Naive 1st line 2nd line 
WHO stage: 
 
1 2 3 4 
Time since HIV diagnosis (months):  
HAART start date:  
Time on HAART:  
Current HAART regimen:  
Time on current HAART:  
Switch from regimen:  
Adherence: 
 
YES NO 
Viral load:  
Previous co-infections:  
Current co-infections:  
Drug history:  
Family history CVD:  
Smoking/snuff:  
Quantity per day:  
Frequency per week:  
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DEMOGRAPHIC QUESTIONNAIRE 
_________________________________________________________________ 
Project title: Cape Winelands HAART to HEART study 
Ethics approval nr: N12/12/086 
                                                    IDENTIFICATION CODE: CWH2H_______  
Date of interview:  
Interviewer:  
Health District 
Site: 
 
Worcester TC Newman Mbekweni Stellenbosch 
Household (Brick 
house, shack other 
dwelling) 
 
Total in household Male Female 
Children 0-6 yrs   
Children 7-12 yrs   
Children 13-18 yrs   
Adults 18-30   
Adults 31-45   
Adults 46-60   
Adults 61+   
LANGUAGE AND ACCULTURATION 
Home language of 
respondent 
Afrikaans Xhosa Zulu English Sotho Other  
Household head speaks Home language only Home language + 
Afr/Eng 
English/Afrikaans only 
Can you read and 
understand a newspaper in 
your home language easily, 
difficult or not at all? 
Easily 1  
With difficulty 2 
Not at all 3 
Can you read and 
understand a newspaper in 
the English language easily, 
difficult or not at all? 
Easily 1  
With difficulty 2 
Not at all 3 
NEAREST CLINIC/HOSPITAL 
Name of clinic/hospital Walk (minutes) Mode of transport 
Walk=1; Taxi=2; Own 
car=3; bicycle=4 
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ANTHROPOMETRY 
Height (m):  
Weight (kg):  
BMI (kg/m2):  
Waist circumference (cm):  
Hip circumference (cm):  
W:H:  
Mid-Upper Arm Circumference (cm):  
Triceps skinfold:  
Biceps skinfold:  
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Appendix 4 
 
 List of reference values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* National Cholesterol Education Program (NCEP) and Adult Treatment Panel III (ATP III) guidelines (NCEP 
Expert Panel 2001). 
◊ IDF clinical criteria (IDF 2006). 
 
 
 
 
 
 
 
 
 
PARAMETER REFERENCE RANGE UNIT 
TC Desirable < 5.2  
Borderline 5.2–6.2  
High > 6.2 
 
mmol/L 
TG Desirable 1.7–2.2  
High > 2.2 
mmol/L 
HDL Desirable > 1.2  
Low < 1 
mmol/L 
LDL Desirable < 2.6  
Borderline 2.6–3.3  
High > 3.3 
 
mmol/L 
CRP Normal < 10 mg/L 
◊FBG Normal 3.9–5.5  
High > 5.6 
mmol/L 
Insulin 
 
Normal 3–25 
High > 25 
mu/L 
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Appendix 5 
 
International Classification of adult underweight, overweight and obesity according to BMI* 
Classification BMI(kg/m2): principal cut-off points 
Underweight < 18.5 
Healthy weight 18.5–24.9 
Class 1 obesity, overweight 25.0–29.9 
Class 2 obesity, obesity 30.0–39.9 
Class 3 obesity, morbid obesity > 40.0 
* Adapted from (WHO 1995; 2000; 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
111 
 
Appendix 6 
 
IDF ethnic specific values for waist circumference (IDF 2006) 
Country/Ethnic groups Waist circumference 
Europids 
In the USA, the ATP III values 
(102 cm male; 88 cm female) 
are likely to continue to be used for 
clinical purposes 
Male  94 cm 
Female  80 cm 
South Asians 
Based on a Chinese, Malay and Asian-Indian 
population 
Male  90 cm 
Female  80 cm 
Sub-Saharan Africans Use European data until more specific data 
are available 
Chinese Male  90 cm 
Female  80 cm 
Japanese Male  90 cm 
Female  80 cm 
Ethnic South and Central Americans Use South Asian recommendations until more 
specific data are available 
Eastern Mediterranean and Middle East 
(Arab) populations 
Use European data until more specific data are 
available 
 
WHR risk categories* 
Gender  Excellent Good Average At risk 
Males < 0.85 0.85–0.89 0.90–0.95 > 0.95 
Females < 0.75   0.75–0.79 0.80–0.86 > 0.86 
 
 World Health Organization cut-off points and risk of metabolic complications (WHO 2011). 
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Appendix 7 
 
Median (IQR) values of blood metabolites HIV-positive (on HAART) persons versus HIV-positive HAART naive 
persons. 
Variables HIV+ HAART naive HIV+ on HAART P-value 
FBG (mmol/l) 
P = 0.053 median 4.6 4.9 
IQR 0.7 0.9 
TC (mmol/l) 
P = 0.4429 Median 3.9 4.3 
IQR 1.22 0.97 
HDL (mmol/l) 
P = 0.0620 Median 0.99 1.29 
IQR 0.52 0.4 
LDL (mmol/l) 
P = 0.7419 Median 2.32 2.46 
IQR 1.37 0.9 
TG (mmol/l) 
P = 0.3616 Median 0.91 1 
IQR 0.39  0.26 
CRP (mg/l) 
P = 0.0585 Median 2 3.2 
IQR 6 7 
Insulin (mu/l) 
P = 0.4821 Median 6.9 6,8 
 IQR 6.1 8.7 
IR HOMA index 
P = 0.4237 Median 1.19 1.44 
IQR 1.47 1.73 
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Appendix 8 
 
Median (IQR) values of blood metabolites for HIV-positive persons on first and second line treatments versus 
HIV-positive HAART naive persons. 
Variables 
HIV+ HAART 
naive 
First line Second line P-value 
FBG (mmol/l)  
P = 0.2209 median 4.6 4.85 4.9 
IQR 0.7 0.95 0.7 
TC (mmol/l) 
P = 0.2090 Median 3.9 4.5 4.01 
IQR 1.22 0.6 1.49 
HDL (mmol/l) 
P = 0.1106 Median 0.99 1.4 1.25 
IQR 0.52 0.4 0.51 
LDL (mmol/l) 
P = 0.2589 Median 2.32 2.65 2.2 
IQR 1.37 0.7 1.21 
TG (mmol/l) 
P = 0.2428 Median 0.91 0.9 1.01 
IQR 0.39 0.4 0.44 
CRP (mg/l) 
P = 0.1665 Median 2 3 3.2 
IQR 6 8.1 5 
Insulin (mu/l) 
P = 0.1854 Median 6.9 5.25 8.1 
 IQR 6.1 6.6 9.5 
IR HOMA index 
P = 0.2046 Median 1.19 1.12 1.69 
IQR 1.47 1.38 1.96 
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